5paisa Capital Ltd
NSE: 5PAISA · BSE: 540776 · ISIN INE618L01018 · Listed Nov 2017 (demerger from IIFL Holdings) · Not in Nifty/Sensex indices · Report date 13 Oct 2026
Quick verdict scorecard
Reconciled figures used throughout this report
| Item | Figure used | Label | Alternative seen / why rejected |
|---|---|---|---|
| P/E (TTM) | 36.8x (₹1,627 Cr ÷ TTM PAT ₹44.2 Cr) | Est. | ~25.9–26.6x on aggregators uses pre-rights EPS (3.125 Cr sh). Post-Giskard swap ~38.4x. 3-yr FY-end avg ~20.9x |
| P/B | 1.44x on Jun-26 BV ₹1,129.5 Cr (₹240.9/sh) | Est. | 2.5x (Screener/Heard) uses stale pre-rights BV ₹138; 1.19–1.20x mixes ex-rights price with pre-rights book |
| Promoter stake post Giskard swap | 34.97% swap-only = 36.5% × 4.688 ÷ (4.688 + 0.2051) | Est. | 34.53% (9 Oct 2026 filing) is a different base: fully diluted incl. ~6.25 lakh ESOPs (+26.76 lakh sh total). Not an error |
| Fairfax holding | 32.76% = FIH Mauritius 24.54% + HWIC Asia 8.22% | Fact | ~35.49% if RIMCO India 2.73% included (governance input treats RIMCO as Fairfax). Apparent "+2.7pp" rise is a definitional artefact, FIH flat 24.55→24.54%. Classified public; no board seat |
| Market share | CRISIL 0.63% overall FY26 (cash ~0.5%, F&O ~0.6%) | Fact | ~0.73% of NSE active clients (Jul-26) Est.; management "~2% in F&O and cash" (Q4 FY26 call) unsupported — possibly share of retail F&O premium ADTO (~1.7% derived) |
| Tax exposure | ~₹49–71 Cr | Est. | ₹33.02 Cr block + ₹15.31 Cr GST (+₹0.94 Cr older GST) = ~₹49 Cr; add ₹21.85 Cr AY23-24 and ₹0.75 Cr AY18-19 if not subsumed by block = ~₹71 Cr |
| Contingent liabilities (Mar-26) | ₹625.8 Cr; ~96% bank guarantees to exchanges backed by FDs | Fact | AR standalone total misprinted ₹685.8 Cr; components and consolidated note sum to ₹625.8 Cr |
| IIFL group ICDs | None in FY25 or FY26 | Fact | CRISIL's ₹500 Cr line is a support facility, undrawn. FY27 omnibus RPT caps ~₹3,580 Cr incl. ICDs given |
| Capitalised software | Q1 FY27 only: ₹7.22 Cr (₹6.79 Cr employee + ₹0.43 Cr other) | Fact | Intangibles under development nil at Mar-26; FY26 D&A ₹9.22 Cr (not ₹32.5 Cr — MD&A swapped finance cost and D&A) |
| "Cross-sell & others 29%" | Mostly interest on lien-marked FDs (₹91.4 Cr) | Fact | Audited cross-sell/commission only ₹1.06 Cr (FY25 ₹15.96 Cr) |
| Giskard (Trendlyne) value | ~₹200 Cr for 96.33%; ~₹207 Cr for 100% (~13x FY25 revenue ₹15.75 Cr) | Est. | Filing item (h) reads ₹121.57 Cr as aggregate (~7.7x); arithmetic ₹11,794 × 1,03,082 = ₹121.57 Cr supports cash-leg-only reading |
Data freshness: prices 13 Oct 2026 close; financials to Q1 FY27 (Jun-26); shareholding Sep-26; Q2 FY27 not yet reported.
Analyst Notes
The editorial read before the data. Analyst View throughout unless labelled.
The business has been shrinking for four years, and the recovery keeps being pushed out. NSE active clients have gone from 17.5 lakh (Mar-22) to 7 lakh, 5 lakh, 4.2 lakh and 3.3 lakh (Mar-26). CRISIL's overall market share fell from 1.2% (FY23) to 0.63% (FY26), below the 0.75% level CRISIL itself names as a downgrade trigger. Revenue peaked at ₹394.7 Cr in FY24, fell to ₹319.9 Cr in FY26, and the analyst on the Q1 FY27 call was right that it has been "flat for about three years". In May 2025 management said the business would "normalize over the next few quarters". Five quarters later PAT is stuck at ₹9.5–12.3 Cr a quarter against ₹20–22 Cr in H1 FY25. The CEO's own letter calls FY26 "a reset rather than a setback". I read it as a setback.
Returns are poor and the rights issue made them worse. FY26 RoNW was 7.1%; Q1 FY27 is 6.9% on the company's basis and 5.2% on CRISIL's; TTM PAT over average equity is ~4.8%. Cost-to-income is ~81% (CRISIL) against an upgrade trigger of <65%. The ₹468.8 Cr rights issue at ₹300 lifted net worth from ₹649 Cr to ~₹1,130 Cr and the share count by 50%, but ₹227 Cr went into exchange margin because RBI barred bank intraday facilities to brokers from 1 Jul 2026, ₹150 Cr repaid banks and CP, and only ~₹88 Cr was earmarked for growth. Within 3.5 months, up to ₹121.57 Cr cash was committed to Trendlyne's parent. At ₹347 the market pays 36.8x trailing earnings for that 5–7% return.
The governance record is the biggest issue. Three CEOs since 2023, including an MD/CEO vacancy (Aug-24 to Jan-25) that breached LODR Reg 26A. Three company secretaries in ~15 months with two ~3-month vacancies. The CCO left in Jun-26 after nine months, the Head of Investing Product left in Sep-26 after eight, and the WTD & CTO — architect of the platform revamp management calls its "biggest bet" — resigned on 30 Sep 2026 with no successor named. The FY26 governance report lists 83 exchange and depository actions, including an NSE warning citing "systemic weaknesses in governance, reporting discipline, and internal control mechanisms". SEBI made a PFUTP finding on AT-1/Tier-II bonds sold as "Bonds for Senior Citizens" and named the sitting CFO as an officer in default. Yet the BRSR reports "zero penalties" and the MD&A claims "a consistent record of compliance without any reported deviations".
The tax and ownership overhangs are real. The Jan-2025 group-wide income-tax search produced a ₹33.02 Cr block assessment on 5 May 2026. It is not in the AR (signed 30 Apr) and is unprovided. Add a ₹21.85 Cr AY23-24 reassessment that may overlap, and a ₹15.31 Cr GST notice: ~₹49–71 Cr, or 1.1–1.6x FY26 PAT. On ownership, Fairfax holds 32.76% (35.5% with RIMCO), almost equal to the promoters' 36.5%, as a passive public holder with no board seat. Fairfax is restructuring its India holdings (IIFL Capital), and any monetisation in a stock with ~16% true retail float and zero domestic institutions would be the single biggest supply event.
Trendlyne raises questions. ~₹207 Cr for 100% of a business with ₹15.75 Cr FY25 revenue and undisclosed profit (~13x sales), on one valuer's DCF dated the same day as an unexplained board-meeting postponement. The cash-leg sellers are undisclosed. IIFL Securities was once an associate shareholder of the target. The filing initially said promoters would buy target shares directly, and that line was withdrawn the next day as "inadvertently included". The swap prices 5paisa at ~₹380, above market, which is mildly favourable to existing holders. Note too that Trendlyne is a common source for this company's own insider data.
The positives are real but are about the balance sheet, not the franchise. Promoters put ~₹206 Cr into the rights issue, about 133% of their entitlement, and have zero pledge. The MTF book has roughly doubled in ~15 months (average funding book ₹260 Cr → ₹422 Cr) at ~18% p.a. client pricing. MTF interest rose 77% in FY26. CRISIL A+/Stable was reaffirmed on IIFL support with the CP limit doubled to ₹400 Cr. Net worth is ~₹1,130 Cr against a ₹1,627 Cr market cap, so P/B is ~1.44x, below the 3-year average of ~2.0x. The AI/API push (MCP integration, AlgoSpace, Xstream APIs, Scalper) is credible product work. Smart money anchors sit at ₹289–300 (Ward Ferry exit, Kela entry, rights price).
What the market is pricing, and what I'd watch. At 36.8x P/E the market is pricing a recovery to well above FY25 peak earnings: a return to the ~21x 3-year average at today's price needs ~₹80 Cr PAT against ₹68 Cr at the peak. That is a bet on capital deployment plus an AI re-rating. The test comes on 15 Oct 2026 (call 16 Oct). Management promised "from this quarter on, you can see an acceleration in growth". If Q2 FY27 shows flat PAT again, falling new adds (Q1 -28% QoQ) and continued active-client erosion, the P/E has no support beyond book. My stance: negative at ₹347; book (~₹241/sh) plus the ₹290–300 smart-money band is where risk/reward starts to balance.
| What to watch while reading | Where | Why it matters |
|---|---|---|
| Active-client and market-share trajectory | Tabs 3, 9 | CRISIL downgrade trigger (0.75%) already breached |
| Interest vs brokerage mix; FD float | Tab 4 | 48% of Q1 FY27 revenue is interest; float is rate-sensitive |
| Q1 FY27 software capitalisation ₹7.22 Cr | Tab 5 | ~47% of Q1 PBT; new practice vs FY26 |
| Rights deployment vs Giskard cash | Tabs 6, 12 | Capital allocation at 5–7% RoNW |
| Leadership exits, NSE QSB warning, SEBI PFUTP | Tab 7 | Control environment |
| Fairfax 32.76% overhang; tax ₹49–71 Cr | Tabs 7, 10 | Supply risk; unprovided liabilities |
Business Deep-Dive
Single reportable segment (broking & related). Asset-light, 100% digital, 100% domestic.
Corporate history and milestones
| Year | Milestone |
|---|---|
| 2007 | Incorporated (CIN L67190MH2007PLC289249) |
| 2016 | Launched as IIFL's online discount-broking arm; NCLT scheme (6 Sep 2017, effective 1 Oct 2016) demerged it from IIFL Holdings, 1 share per 25 IIFL shares — why Fairfax's register mirrors IIFL |
| Nov 2017 | Listed NSE/BSE (~1.27 Cr shares, FV ₹10) |
| FY19 / Aug-2019 | 1 lakh customers; ₹101 Cr rights issue (promoters took 49,32,734 sh) |
| FY21 | 10 lakh customers; positive unit economics |
| May 2021 | ₹250 Cr raise at ₹500: preferential to FIH Mauritius (~₹44.9 Cr), HWIC Asia, RIMCO, WF Asian Reconnaissance + 12 lakh promoter warrants (₹60 Cr) |
| Aug 2022 | ₹45 Cr of warrants converted (~₹15 Cr lapsed) |
| Mar-22 | Peak 17.5 lakh NSE active clients |
| 2023 | FnO360 platform launched |
| 2024 | Web Trade Station 2.0; TradingView charts; 14 Mar 2024 MCX/NSE/BSE onboarding bar (Bombay HC stay) |
| FY25 | Record ADTO ₹3.8 tn+; record PAT ₹68.2 Cr; CEO Gaurav Seth from Jan-25 |
| 2025–26 | Pay Later MTF revamp, Scalper, MCP/LLM integration, MF dashboard, ETF revamp; crossed 5 Mn customers |
| Apr 2026 | ₹468.82 Cr rights issue (1:2 at ₹300) |
| 20 Jun 2026 | AlgoSpace launched at BSE Algo Convention |
| 28 Jul 2026 | Board approves Giskard Datatech (Trendlyne) acquisition |
Products and services
| Product | What it does | Monetisation |
|---|---|---|
| Cash equity (delivery/intraday) | NSE/BSE trading; "₹0 brokerage for 30 days" promo | ₹20/executed order or 25 paise/share for stocks ≤₹10 |
| F&O (index/stock) | Historically dominant: ~80% derivatives / 20% cash of revenue (Jul-25 call); "F&O-heavy base" (CEO) | ₹20/order |
| Commodity (MCX) & currency | MCX member 55945; MCX awards 2022, 2025 | ₹20/order |
| FnO360 | Option chain, Strategy Analyzer (payoff, Greeks, 50+ scanners), Alpha Scan, OI analytics | Brokerage |
| Scalper | 3-in-1 chart terminal for fast intraday options execution | Brokerage |
| Advanced orders | VTT, slicing, basket, bulk, quick reverse, OneClick, OI profile on charts | Brokerage |
| AlgoSpace | No-code algo marketplace (equity/options/futures), backtests; zero platform fee | Brokerage only |
| Xstream open APIs / XTS / co-location | Zero-cost trading and market-data API; "Xstream AI" assistant; Greeks, 20-depth, static IP | Brokerage; 71 API/fintech partners |
| MCP / LLM integration | Conversational analyse-and-trade; named as Claude in Q1 FY26 call (AlphaStreet), later "a major LLM provider" | Engagement |
| Multi-platform | App (23.8 Mn installs, 4.3★), web, Windows EXE, TradingView charts | — |
| Mutual funds | Direct/regular MF, 0% commission (ARN-104096); MF AUM ₹2,073 Cr; 13.68 lakh active SIPs | Low yield |
| IPOs, NFOs, ETFs, stock SIPs | ETF revamp 2026 | — |
| US stocks | Via partner Vested | Revenue share (n.d.) |
| Portfolio Intelligence / AI Insights & DYOR | Health score, rebalancing, deep-research chat, thematic baskets | Engagement |
| Research / advisory | SEBI RA INH000025188 (re-granted 26 Feb 2026); AI research calls, chart patterns, options intelligence | Subscription packs ("Ultra Trader"/"Power Investor") no longer shown INFERRED |
| Insurance / TPD | None; "near future no… midterm we'll consider" (NPS, LAS/LAMF next) | Cross-sell ₹1.06 Cr FY26 |
| Partners | smallcase, ClearTax, MarketSmith India, Intraedge, Vested | n.d. |
Client funding products (MTF "Pay Later" and T+5)
| Term | MTF (Pay Later) | T+5 |
|---|---|---|
| Coverage | 1,500+ stocks (from ~700) | 2,500 non-MTF scrips |
| Leverage | Up to 4x | 2x |
| Client limit | Up to ₹25 Cr (Q1 FY27 call; AR says ₹3 Cr) | — |
| Interest | 0.049%/day (~18% p.a.) | From 0.045%/day |
| Other | ₹20/order; free pledge/unpledge; day-0 activation | BTST and CUSPA variants |
Licences, registrations and certifications
| Registration | Number / detail |
|---|---|
| SEBI stockbroker | INZ000010231; Qualified Stock Broker (QSB) |
| Exchanges | NSE 14300, BSE 6363, MCX 55945 |
| Depository | CDSL only, IN-DP-192-2016 |
| Research Analyst | INH000025188 (lapsed Oct-25, re-granted 26 Feb 2026) |
| Investment Adviser | Being surrendered; SEBI SCN 8 Jun 2026 over unpaid fees |
| AMFI | ARN-104096 (since Jul 2015) |
| RBI | 5paisa P2P Ltd NBFC-P2P (CoR N-13.02371) |
| Certification | ISO 27001:2013; "Defense in Depth" cyber framework. No patents |
Platform, technology and operations
- 100% paperless eKYC. DIY onboarding share: 86.4% (Q4 FY25), 85.5%, 90.5%, 94.6%, 96.6%, 96.8% (Q1 FY27). STP acquisitions 96.6% (AR).
- In-house engineering, about 33%/200+ of staff in tech/product; "dedicated AI charter". The "complete platform revamp" (15–18 months of work) was in beta at Jul-26; the CTO resigned 30 Sep 2026.
- Stack: XTS APIs (Symphony Fintech INFERRED), TradingView charting, exchange co-location, Google Cloud hosting INFERRED, unnamed LLM for MCP. 99.98% crash-free sessions; 50 ms latency cut; market-feed payload -50%.
- Customer service in-house (Dhruv Kapadia); FinSchool investor-education arm; Options & Algo Conventions and Traders Summits.
- Facilities: no manufacturing. Head office in IIFL House, Thane, rented from IIFL Facilities Services (₹2.09 Cr FY26). GIFT City subsidiary. Trendlyne (Bengaluru) office on closing. Area not disclosed.
- Exports: none; 100% domestic. US-stock access via Vested and the non-operational IFSC unit are the only cross-border touchpoints.
Customer funnel and engagement (FY26 AR and decks)
| Metric | Mar-24 | Mar-25 | Mar-26 | Jun-26 |
|---|---|---|---|---|
| Registered customers (lakh) | 42.3 | 48.3 | 51.9 | 52.6 |
| NSE active clients (lakh) | 5.0 | 4.2 | 3.35 (AR 3,34,970) | 3.31 (Jul-26) |
| Active / registered | 11.8% | 8.7% | 6.5% | ~6.3% |
| New clients in year/quarter (lakh) | — | ~6.0 (FY25) | 3.6 (FY26) | 0.74 (Q1) |
| DAU / MAU (lakh) | — | — | 1.70 / 6.60 | — |
| App installs (Mn) | — | — | 23.4 | 23.8 |
Other AR KPIs: 92% of new clients from Tier 2/3; ~75% of clients in Tier 2/3 (Q1 FY26 call); 62% of clients <35 years; orders 91.57 Mn FY26; ADTO ₹2.90 tn (-6%). AR MD&A calls 5paisa "the second-largest discount broker by client base" — a registered-client framing not supported by activity.
Pending acquisition: Giskard Datatech Pvt Ltd (Trendlyne)
| Item | Detail |
|---|---|
| Target | Incorporated 13 Jun 2016, Bengaluru; SEBI RA; runs Trendlyne (screeners, analytics, research, alerts, datasets, "MarketMind" AI); ~1.5 Mn MAU; 40+ institutional clients |
| Turnover | FY23 ₹7.66 Cr; FY24 ₹12.07 Cr; FY25 ₹15.75 Cr; profit not disclosed |
| Valuation | DCF ₹11,794/sh (registered valuer Raghav Mandhana, IBBI/RV/06/2025/15965; report 18 Jun 2026) |
| Cash leg | Up to ₹121.57 Cr for up to 1,03,082 sh (58.68%); sellers undisclosed |
| Swap leg | 20,50,588 new 5paisa sh (1:31; exact 1:31.0368) for 66,148 sh (37.65%) — Amber Pabreja 11,82,588; Devi Yeshodharan 8,68,000 (Trendlyne founders UNVERIFIED) |
| Implied value | ~₹200 Cr for 96.33%; ~₹207 Cr for 100% Est.; swap implies ~₹380/5paisa share; remaining ~3.67% unaddressed |
| Disclosure correction | 28 Jul outcome said promoters would buy GDPL shares directly for the cash leg; withdrawn 29 Jul as "inadvertently included" — "no proposal for the promoters… to acquire shares of GDPL" |
| Approvals | Postal ballot 29 Jul–27 Aug 2026 passed 99.99% (3.58 Cr votes for, 4,085 against); corrigendum 21 Aug; SEBI RA change-of-control approval and exchange in-principle pending; completion ~Jan 2027 |
| Group linkage | IIFL Securities bought an additional 6.25% (Sep 2020, making it an associate) and sold its ~20.55–21.47% in Dec 2021 to IIFL Capital Enhance Fund (IIFL-affiliated AIF). Company says not an RPT |
| Funding / rating | Rights proceeds + accruals; CRISIL sees no rating impact |
Segment & Revenue-Mix Analysis
One reportable segment, so there is no segment EBITDA. Revenue is analysed by stream.
Audited revenue breakdown FY26 vs FY25 (standalone, ₹ Cr; AR Notes 21–22)
| Line | FY26 | FY25 | YoY | % of FY26 rev |
|---|---|---|---|---|
| Interest on bank deposits (FDs lien-marked to exchanges/banks) | 91.37 | 103.77 | -11.9% | 29% |
| Interest on MTF loans | 47.16 | 26.65 | +77.0% | 15% |
| Interest income total | 138.53 | 130.41 | +6.2% | 43% |
| Brokerage & related income (incl. DP/other fees) | 179.95 | 213.20 | -15.6% | 56% |
| Commission & other (cross-sell/distribution) | 1.06 | 15.96 | -93.3% | 0.3% |
| Fees & commission total | 181.02 | 229.16 | -21.0% | 57% |
| Revenue from operations | 319.55 | 359.57 | -11.1% | 100% |
Management split (MD&A / decks, ₹ Cr)
| Period | Brokerage | Allied broking | Other operating | Total | Mix B/A/O |
|---|---|---|---|---|---|
| FY25 | 171.4 | 88.6 | 99.8 | 359.8 | 48/25/28 |
| FY26 | 149.3 | 78.3 | 92.3 | 319.9 | 47/24/29 |
| Q1 FY26 | 35.6 | 18.0 | 24.2 | 77.8 | 46/23/31 |
| Q2 FY26 Est. | ~34.8 | ~19.3 | ~23.2 | 77.3 | 45/25/30 |
| Q3 FY26 Est. | ~37.3 | ~19.8 | ~22.2 | 79.3 | 47/25/28 |
| Q4 FY26 | 41.9 | 20.7 | 22.9 | 85.5 | 49/24/27 |
| Q1 FY27 | 39.4 | 21.6 | 27.4 | 88.4 | 45/24/31 |
| Q1 FY27 YoY / QoQ | +11% / -6% | +20% / +4% | +13% / +20% | +14% / +3% |
Mapping MD&A streams to audited notes INFERRED
"Other operating" ₹92.3 Cr ≈ FD interest ₹91.4 Cr. "Allied" ₹78.3 Cr ≈ MTF interest ₹47.2 Cr + ~₹31 Cr of DP/other fees carved from brokerage. Brokerage ₹149.3 Cr + ₹31 Cr ≈ audited ₹180.0 Cr + ₹1.06 Cr cross-sell. FY25 does not reconcile cleanly, so indicative only. The AR p.4 pie labels 29% "Cross-sell & others"; it is essentially float interest on lien-marked FDs, largely funded by client money. Audited cross-sell is ₹1.06 Cr. No F&O vs cash split of brokerage is disclosed.MTF / client funding book
| Metric | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Avg MTF book (₹ Cr) | 325.8 | 335.9 | 366.6 | 405.3 |
| Avg funding book MTF+T+5 (₹ Cr) | 366 | 380 | 410 | 421.6 |
| Avg per-client exposure (₹) | 2,28,728 | 2,20,089 | 2,21,256 | 2,78,600 |
| Clients < ₹1L exposure | 77.6% | 77.5% | 77.3% | 70.7% |
| Clients ₹1–5L | 13.6% | 13.6% | 13.9% | 18.7% |
| Clients > ₹5L | 8.9% | 9.0% | 8.9% | 10.6% |
Other MTF bases: CEO letter MTF book ₹179 Cr → ₹326 Cr in FY26 (+82%); audited MTF loans ₹224.9 Cr (Mar-25) → ₹340.4 Cr (Mar-26); FY26 average funding book ₹367.9 Cr (+40%); loans granted in FY26 ₹6,700 Cr aggregate (CARO). Implied ~14,500 MTF borrowers Est.. Implied MTF yield ~12.8% on average book vs borrowing cost ~8.9% Est.. Management (Q1 FY27): book "much higher now"; claimed "+10% QoQ" vs reported +3%.
Q1 FY27 cost structure (₹ Cr)
| Line | Amount | % of income | Comment |
|---|---|---|---|
| Employee cost (after capitalising ₹6.79 Cr) | 22.1 | 25% | -13% QoQ, +8% YoY; gross ~₹28.9 Cr |
| Other expenses | 40.2 | 45% | +25% YoY: growth marketing, acquisition |
| Finance cost | 8.45 | 10% | +16% YoY, -7% QoQ |
| D&A | 2.21 | 2.5% | |
| PBT | 15.45 | 17.5% | ~₹8.2 Cr ex-capitalisation Est. |
Unit economics Est.
| Metric | Value | Basis |
|---|---|---|
| Revenue per active client per year | ~₹8,500 | ₹320 Cr / ~3.75 lakh avg actives |
| Orders per active client per quarter | ~76 | 25.1 Mn / 3.3 lakh |
| Brokerage per order | ~₹16 | ₹39.4 Cr / 25.1 Mn orders |
| Annual gross employee cost | ~₹115 Cr | (₹22.1 + ₹6.8 Cr) × 4 |
Financials: P&L
Consolidated, ₹ Cr. EBITDA = PBT + finance cost + D&A (broker definition; no COGS). Company "EBDTA" = PBT + D&A is shown separately.
Five-year P&L line items
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|
| Interest income | 81.0 | 101.9 | 135.2 | 130.41 | 138.54 | 42.17 |
| Fees & commission | 216.0 | 236.0 | 259.4 | 229.16 | 181.02 | 46.16 |
| Revenue from operations | 297.0 | 337.9 | 394.6 | 359.57 | 319.56 | 88.33 |
| Other income | ~0.8 | ~1.5 | ~0.1 | 0.28 | 0.34 | 0.05 |
| Total income | 297.8 | 339.4 | 394.7 | 359.85 | 319.89 | 88.38 |
| Finance cost | 23 | 21 | 29 | 23.80 | 32.53 | 8.45 |
| Employee benefits | 42.2 | 59.1 | 89.5 | 74.03 | 88.62 | 22.10 |
| D&A and impairment | 5 | 9 | 10 | 12.22 | 9.22 | 2.21 |
| Other expenses | ~209 | ~192 | ~194 | 158.57 | 130.23 | 40.17 |
| PBT | 18.5 | 58.1 | 72.1 | 91.22 | 59.29 | 15.45 |
| Tax | 4.8 | 14.5 | 17.7 | 22.99 | 15.11 | 3.88 |
| PAT | 13.7 | 43.6 | 54.4 | 68.23 | 44.19 | 11.57 |
| Diluted EPS (₹, reported) | 4.68 | 14.33 | 16.67 | 21.79 | 14.13 | 2.60 |
FY25–Q1 FY27 audited/limited-review filings; FY22–24 S&P (StockAnalysis) and Screener; FY22–24 other expenses are residuals (approx.). FY20 was a loss (₹-8 Cr); FY21 PAT ₹15 Cr on ₹195 Cr income. Standalone FY26 PAT ₹44.12 Cr (EPS basic ₹14.12). Correction: the AR MD&A table swaps finance cost (₹32.5 Cr) and D&A (₹9.2 Cr) and says finance cost "declined"; audited figures above are correct.
Profit lines and margins (% of total income)
| ₹ Cr / % | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| YoY total income growth | +53% | +14% | +16% | -9% | -11% |
| Net revenue (income less finance cost) | 274.8 | 318.4 | 365.7 | 336.1 | 287.4 |
| Net revenue margin | 92.3% | 93.8% | 92.7% | 93.4% | 89.8% |
| EBITDA | 46.5 | 88.1 | 111.1 | 127.2 | 101.0 |
| EBITDA margin | 15.6% | 26.0% | 28.1% | 35.4% | 31.6% |
| EBIT | 41.5 | 79.1 | 101.1 | 115.0 | 91.8 |
| EBIT margin | 13.9% | 23.3% | 25.6% | 32.0% | 28.7% |
| PBT margin | 6.2% | 17.1% | 18.3% | 25.3% | 18.5% |
| PAT margin | 4.6% | 12.8% | 13.8% | 19.0% | 13.8% |
| Effective tax rate | 25.8% | 25.0% | 24.5% | 25.2% | 25.5% |
| Cost-to-income (CRISIL basis) | — | — | 80% | 73% | 79% |
5-yr CAGR (FY21–26): income ~10%; PAT ~25%. FY23–26 revenue CAGR ~-2%. Cost-to-income alternatives: company ~75% (FY25), ~81% (FY26 CEO letter); Q1 FY27 81% CRISIL / 83% company.
Last 8 quarters
| Quarter | Total income | YoY | QoQ | EBITDA | EBITDA % | PBT | PAT | PAT YoY | PAT QoQ | Dil. EPS ₹ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY25 (Sep-24) | 100.8 | +4% | -1% | ~38.5 | 38% | 29.31 | 21.90 | +14% | +9% | 6.96 |
| Q3 FY25 (Dec-24) | 85.3 | -15% | -15% | ~30.2 | 35% | 21.55 | 16.18 | +7% | -26% | 5.15 |
| Q4 FY25 (Mar-25) | 71.41 | -37% | -16% | 21.31 | 29.8% | 13.47 | 10.07 | ~+70%* | -38% | 3.22 |
| Q1 FY26 (Jun-25) | 77.77 | -24% | +9% | 25.28 | 32.5% | 15.50 | 11.55 | -43% | +15% | 3.68 |
| Q2 FY26 (Sep-25) | 77.30 | -23% | -1% | 23.10 | 29.9% | 12.74 | 9.48 | -57% | -18% | 3.03 |
| Q3 FY26 (Dec-25) | 79.34 | -7% | +3% | 26.90 | 33.9% | 16.53 | 12.30 | -24% | +30% | 3.93 |
| Q4 FY26 (Mar-26) | 85.48 | +20% | +8% | 25.76 | 30.1% | 14.52 | 10.86 | +8% | -12% | 3.47 |
| Q1 FY27 (Jun-26) | 88.38 | +14% | +3% | 26.11 | 29.5% | 15.45 | 11.57 | +0.2% | +7% | 2.60 |
*Low base (Q4 FY24 PAT ~₹6 Cr). Q2 FY26 derived from FY26 audited less other quarters; Q2–Q3 FY25 from S&P with ~₹3.2 Cr/qtr D&A. Company "EBDTA" (PBT + D&A): Q1 FY26 ₹18.0 Cr, Q2 ₹15.1, Q3 ₹18.7, Q4 ₹16.7, Q1 FY27 ₹17.7 Cr (20–24% margin). Q1 FY27 operating margin -292 bps YoY (MarketsMojo). Company-reported RoNW: Q4 FY25 6.7%, Q1 FY26 7.6%, Q2 6.1%, Q3 7.8%, Q4 6.7%, Q1 FY27 6.9%.
Q1 FY27 operating KPIs
| KPI | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|
| New clients (lakh) | 0.91 | 0.80 | 0.95 | 0.78 | 1.03 | 0.74 |
| Registered base (lakh) | 48.3 | 49.1 | 50.1 | 50.8 | 51.8 | 52.6 |
| ADTO (₹ tn, notional) | 1.93 | 2.25 | 2.68 | 3.31 | 3.40 | 3.04 |
| MF AUM (₹ Cr) | 1,392 | 1,573 | — | 1,868 | 1,761 | 2,073 |
| DIY onboarding | 86.4% | 85.5% | 90.5% | 94.6% | 96.6% | 96.8% |
| Orders (Mn) | — | — | — | — | 26.3 | 25.1 |
One-time items and earnings quality
| Item | Period | ₹ Cr | Effect |
|---|---|---|---|
| ESOP/RSU reversal (net SBP credit; gross unvested reversal ₹8.66 Cr) | FY25 | +5.79 | Flattered FY25 peak |
| ESOP charge | FY26 | -2.55 | Ex-SBP, PBT fell ~28% (₹85.4 → ₹61.7 Cr) vs reported -35% |
| Labour-code past-service cost | Q3 FY26 | -0.62 | One-off |
| Software capitalised (Ind AS 38): ₹6.79 Cr employee + ₹0.43 Cr other | Q1 FY27 | +7.22 | ~47% of Q1 PBT (~₹5.4 Cr post-tax); none in FY26 (intangibles under development nil) |
| MCX penalty ₹2.60 Cr | FY25 | provided | SAT appeal pending |
Are profits backed by cash?
Cumulative 5-yr PAT ₹224.1 Cr vs cumulative OCF ₹-213.5 Cr; OCF negative in FY22, FY24, FY26. This is mostly mechanical: client-money timing and MTF loan growth are classified as operating. Pre-working-capital cash profit (₹105–122 Cr/yr) runs 1.8–2.4x PAT, so it is not an accrual red flag. But growth is balance-sheet funded (₹161 Cr new debt in FY26, then the rights issue). The new Q1 FY27 capitalisation is the earnings-quality watch item: it inflates PAT relative to cash.Financials: Balance Sheet, Cash Flow & Ratios
Broker balance sheet: ~72% of assets are lien-marked FDs largely funded by client money. Inventory days, debtor days and CCC are n.m.; EV/EBITDA n.m.
Balance sheet (consolidated, ₹ Cr, 31 Mar)
| Item | FY22 | FY23 | FY24 | FY25 | FY26 | Jun-26 |
|---|---|---|---|---|---|---|
| Fixed assets (PPE + ROU + intangibles) | 11.4 | 15.5 | 24.9 | 20.0 | 17.6 | n.d. |
| — of which ROU | — | — | — | 11.18 | 11.24 | |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory (trading securities) | 12.2 | 6.4 | 0 | 0 | 0 | |
| Trade receivables | 81.1* | 100.3* | 137.6* | 0.05 | 0.19 | |
| Loans (MTF / margin funding) | ~277* | ~197* | ~220* | 224.9 | 340.4 | |
| Cash & cash equivalents | 89.4 | 20.9 | 70.9 | 20.3 | 37.3 | |
| Other bank balances (incl. client FDs) | ~1,123* | ~1,293* | ~1,583* | 1,316.3 | 1,380.4 | |
| Other financial assets (exchange margin etc.) | — | — | — | 65.6 | 110.8 | |
| Total assets | 1,608.6 | 1,641.6 | 2,047.9 | 1,667.3 | 1,907.1 | ~2,260 Est. |
| Total debt (ex-leases) | 279 | 169 | 336 | 217.4 | 378.6 | ~339 Est. |
| — Commercial paper | — | — | — | 0 | 74.2 | |
| — Bank WCDL / OD | — | — | — | 217.4 | 304.3 | |
| Lease liabilities | 2.8 | 2.4 | 15.0 | 12.1 | 12.6 | |
| Client & other financial liabilities + payables | ~956 | ~1,009 | ~1,172 | 773.0 + 57.0 | 815.0 + 57.2 | |
| Net worth | 374.0 | 463.3 | 539.9 | 603.6 | 649.2 | 1,129.5 |
| Equity share capital | 29.4 | 30.6 | 31.2 | 31.24 | 31.25 | 46.88 |
| BVPS (₹) | 127.1 | 151.2 | 173.1 | 193.3 | 207.7 | 240.9 |
*S&P classification differs from Ind AS; indicative only. Jun-26 net worth from Reg 52(4) annexure; debt derived from D/E 0.30; assets from debt/assets 0.15. Assets pledged as security (standalone): FDs ₹1,380.0 Cr + other financial assets ₹388.1 Cr = ₹1,768.1 Cr (93% of total assets).
Client funds and lien-marked deposits (standalone, ₹ Cr, 31 Mar)
| Item | FY26 | FY25 |
|---|---|---|
| Cash & bank: current accounts | 15.37 | 0.84 |
| Cash & bank: client accounts | 21.62 | 19.23 |
| Fixed deposits, 100% lien-marked (BG/OD and exchange margin) | 1,380.00 | 1,315.89 |
| Deposit / margin with exchanges | 13.20 | 8.58 |
| Clients & exchanges receivables (net) | 48.24 | 12.03 |
| Interest accrued on deposits | 44.55 | 40.41 |
| Clients & exchanges payables (client money owed) | 797.14 | 756.23 |
| MTF loans (repayable on demand, secured by pledged securities) | 340.37 | 224.89 |
| Standalone net worth | 649.97 | 604.45 |
Q1 FY26 call: cash and bank ~₹1,400 Cr, of which ~₹500 Cr own and ~₹900 Cr client. Gross float interest (~₹70 Cr) is of the order of annual profit; management says net float income is lower after BG and funding costs.
Cash flow (consolidated, ₹ Cr)
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| PAT | 13.7 | 43.6 | 54.4 | 68.2 | 44.2 |
| Operating profit before WC changes | — | — | — | 121.9 | 104.8 |
| Change in loans (MTF) | — | — | — | -49.3 | -115.5 |
| Change in bank deposits | — | — | — | +250.2 | -64.2 |
| Change in client liabilities | — | — | — | -302.9 | +42.1 |
| Change in other financial assets | — | — | — | +126.6 | -45.2 |
| OCF | -140.6 | 24.6 | -91.7 | 97.9 | -103.7 |
| Capex (PPE + intangibles) | -7.5 | -13.6 | -19.4 | -8.0 | -6.9 |
| FCF (OCF − capex) | -148.1 | 11.0 | -111.1 | 89.9 | -110.6 |
| CFI | -12.0 | -8.1 | -12.5 | -7.0 | -6.7 |
| CFF | 225.2 | -85.0 | 154.2 | -141.5 | 127.3 |
| Net debt raised / (repaid) | +45.0 | -109.7 | +167.0 | -118.9 | +161.1 |
| Equity issued (net) | +187.0 | +45.3 | +15.7 | +1.1 | -1.3 |
| Cash taxes paid | 2.9 | 3.5 | 16.4 | 20.1 | 18.3 |
| FCF yield on FY-end mcap | -14.6% | +1.3% | -7.1% | +8.1% | -14.2% |
FY26 net debt raised = OD +₹86.9 Cr, CP +₹74.2 Cr. FCF yield on current mcap ₹1,627 Cr: -6.8%. Capex is maintenance-level (₹7–19 Cr/yr); asset turns n.m. for a broker.
Working-capital metrics
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Debtor days | n.m. | n.m. | n.m. | n.m. | n.m. (0.2 days) |
| Inventory days | n.m. | n.m. | n.m. | n.m. | n.m. |
| Creditor days | n.m. | n.m. | n.m. | n.m. | n.m. (~930 on client float) |
| Cash conversion cycle | n.m. | n.m. | n.m. | n.m. | n.m. |
| Working-capital days (Screener) | -1,026 | -941 | -899 | -785 | -865 |
| MTF loans as days of revenue (the real driver) | ~340* | ~213* | ~204* | 228 | 388 |
Ratios
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 | Q1 FY27 / TTM |
|---|---|---|---|---|---|---|
| RoE (avg equity) | 5.2% | 10.4% | 10.9% | 11.9% | 7.05% | 6.9% co. / 5.2% CRISIL / ~4.8% TTM |
| RoCE | ~7.9% | ~12.2% | ~13.2% | ~13.4% (AR 13.6%) | ~9.9% (AR 8.9%) | |
| D/E | 0.75 | 0.37 | 0.65 | 0.38 | 0.58 | 0.30 |
| Interest coverage (EBIT/finance cost) | 1.8x | 3.8x | 3.5x | 4.8x | 2.8x | 2.8x |
| ISCR / DSCR (company) | — | — | — | — | 2.60 / 2.84 | 2.83 / 3.09 |
| Current ratio | 1.29 | 1.38 | 1.36 | 1.56 | 1.50 | 1.93 |
| Asset turnover | 0.22 | 0.20 | 0.20 | 0.18 | 0.16 | |
| Net profit margin | 4.6% | 12.8% | 13.8% | 19.0% | 13.8% | 13% |
| Total debt / total assets | — | — | — | — | 0.20 | 0.15 |
| Bad debts to receivables | — | — | — | — | 0.01x | 0.01x |
Borrowings, lenders and credit rating
| Instrument (standalone, 31 Mar) | FY26 ₹ Cr | FY25 ₹ Cr | Security | Tenor | Rate |
|---|---|---|---|---|---|
| Commercial paper | 74.24 | nil | Unsecured | <1 yr | 8.30–9.10% |
| Working capital demand loans | 210.00 | 129.45 | Secured, 1.75x cover on receivables/current assets | 7–365 days, bullet | MCLR + 0.75–1.50% |
| Bank overdraft | 94.32 | 87.96 | Against bank FDs | On demand | FD rate + 0.50–1.00% |
| Loans from related parties (IIFL group) | nil | nil | Unsecured | On demand | SBI 1-yr MCLR + 2.5–3.5% (framework only) |
| Total ex-lease | 378.56 | 217.42 | Lease liabilities ₹12.57 Cr (<1 yr 3.50; 1–2 yr 4.05; 2–5 yr 5.02) | ||
| Lender (CP Letter of Offer, 27 Jan 2026; CRISIL bulletin 20 Jan 2026) | Facility | ₹ Cr |
|---|---|---|
| SBM Bank | OD/WCDL against FD | 29.10 |
| HDFC Bank | OD/WCDL against FD | 25.51 |
| Indian Bank | OD/WCDL against FD | 23.55 |
| Bandhan Bank | OD/WCDL against FD | 18.16 |
| DCB Bank | OD/WCDL against FD | 12.45 |
| Federal Bank | OD/WCDL against FD | 8.64 |
| Aditya Birla Finance / Capital | WCDL against receivables (CRISIL: ABCL ₹40 Cr) | 40–100 |
| IDFC First Bank | WCDL against receivables (CRISIL: ₹150 Cr) | 60–75 |
| IDBI Bank | Bank guarantee | 75 |
| ICICI Bank | CP issuing & paying agent | — |
Unutilised lines ₹366 Cr (Jun-26, CRISIL). All debt short-term (no term loans, no NCDs outstanding). CARO: no defaults, no diversion of short-term funds. Post-rights ₹150 Cr repaid to banks/CP (CFO, Jul-26); CPs redeemed 9 Oct 2026. Board approved NCDs up to ₹250 Cr/yr by private placement (30 Apr 2026; AGM 1 Sep 2026 passed). From 1 Jul 2026 RBI barred bank intraday facilities to brokers.
| CRISIL rating (letter 25 Aug 2026) | ₹ Cr | Rating | Action |
|---|---|---|---|
| NCDs | 50 | A+/Stable | Reaffirmed |
| NCDs (new) | 50 | A+/Stable | Assigned |
| Long-term bank loan facility | 100 | A+/Stable | Reaffirmed |
| Short-term bank loan facility | 300 | A1+ | Reaffirmed |
| Commercial paper | 400 (from 200; from 100 in Aug-25) | A1+ | Reaffirmed |
Rating rests on IIFL promoter-group support (₹500 Cr ICD support line from IIFL Finance, IIFL Capital Services, 360 ONE WAM — ₹600 Cr until Feb-25 — undrawn in FY25 and FY26). Downgrade triggers: market share below 0.75% for a prolonged period (breached at 0.63%); material change in IIFL support or holding. Upgrade trigger: cost-to-income <65%. No ICRA/CARE/India Ratings rating. Prior reaffirmations: 23 Sep 2024, 12 Feb 2025, 26 Aug 2025.
Equity dilution and share-count history
| Date | Event | Shares (Cr) | Notes |
|---|---|---|---|
| Nov 2017 | Listing post demerger | ~1.27 | Equity ₹12.7 Cr |
| FY19–FY20 | Rights issue ₹101 Cr | ~2.55 | Equity ₹25.5 Cr |
| FY21 | ESOP | ~2.6 | |
| FY22 | Preferential at ₹500 (₹187–190 Cr cash) to FIH, HWIC, RIMCO, WF Asian | 2.94 | Promoter 34.53% → 29.95% |
| FY23 | Promoter warrant conversion ₹45 Cr (~₹15 Cr lapsed) | 3.06 | Promoter 29.95% → 33.33% |
| FY24 | ESOP ₹15.7 Cr | 3.12 | Diluted 3.27 vs basic 3.09 that year |
| FY25 | ESOP ₹1.1 Cr | 3.124 | |
| FY26 | ESOP: 6,000 sh (8 Aug 2025), 12,500 sh (4 Feb 2026) | 3.1255 | 3,12,54,838 sh |
| 13 Apr 2026 | Rights 1:2 at ₹300; 1,56,27,419 sh = ₹468.82 Cr; 1.24x (123.67%) | 4.688 | +50%; expenses ₹1.49 Cr to premium |
| Pending (~Jan 2027) | Giskard swap 20,50,588 sh at ~₹380 | 4.893 | +4.4%; fully diluted incl. ESOPs 4.956 |
| Rights use | Letter of offer ₹ Cr | Actual (CFO, Jul-26) ₹ Cr |
|---|---|---|
| Exchange margin deposits | 227.00 | 227 (deployed; RBI rule 1 Jul 2026) |
| Repayment of borrowings | 150.00 | 150 (banks and CP) |
| General corporate purposes | 88.08 | 88 (product, tech, marketing) |
| Total | 465.08 | ~465–468 (CFO's "₹268 Cr" a misstatement) |
Board approved rights up to ₹475 Cr (24 Feb 2026); terms 11–12 Mar; record date 17 Mar; open 27 Mar–10 Apr; listed ~16 Apr. Utilisation is not in the AR (no monitoring-agency statement). Giskard cash (up to ₹121.57 Cr) exceeds the ₹88 Cr GCP bucket — funded by "rights proceeds plus accruals" per CRISIL. ESOP overhang: ESOP 2017 7,18,400 + ESOP 2023 25,000 ≈ 7.43 lakh (1.6%); 9 Oct 2026 filing shows 6.25 lakh (1.26%). No QIP, bonus, split, dividend or buyback ever.
Contingent liabilities (AR Note 30, ₹ Cr)
| Item | FY26 | FY25 |
|---|---|---|
| Bank guarantees to exchanges / clearing corps | 602.00 | 500.00 |
| Income-tax matters (AY23-24 ₹21.85 Cr; AY18-19 ₹0.75 Cr; other) | 23.54 | 21.85 |
| Legal cases / penalties | 0.26 | 0.27 |
| Total (components; consolidated note) | 625.81 | 522.12 |
Management, Promoters & Governance
Primary source: FY26 Annual Report (CG report, secretarial audit, Notes 30/32/34), AGM notice and voting results, SHP Jun-26.
| Area | Assessment | Key evidence |
|---|---|---|
| Promoter alignment | Mixed-positive | Took 44% of the rights (~₹206 Cr); stake 32.76% → 36.50%; nil pledge |
| Control structure | Watch | Fairfax 32.76% (35.5% with RIMCO) vs promoters 36.5%; Fairfax public, no board seat |
| Board | Adequate, thinning | 5 IDs + 2 EDs after CTO exit; Chair on 5 other listed boards |
| KMP stability | Red flag | 3 CEOs in 3 years; Reg 26A breach; 3 CSs in ~15 months; CCO, CTO, product head exits 2026 |
| Regulatory record | Red flag | 83 exchange/depository actions; NSE QSB "systemic weaknesses" warning; SEBI PFUTP finding |
| Tax | Red flag | ₹33.02 Cr block + ₹21.85 Cr AY24 + ₹15.31 Cr GST: ~₹49–71 Cr |
| RPT | Watch | Omnibus caps ~₹3,580 Cr incl. ICDs given; actual FY26 flows ~₹7 Cr, no ICDs |
| M&A | Watch | Giskard ~₹207 Cr, ~13x revenue; disclosure corrected in 24h |
| Auditor | Clean, with EoM | Unmodified; EoM on IT search; one KAM (IT systems); rotation due 2027 |
| Disclosure quality | Watch | CL total mis-added; MD&A line swap; pay ratios on wrong names; BRSR "zero penalties" |
Promoter group (Jun-26: 36.50%, 1,71,13,393 sh, 0% pledged/NDU/encumbered)
| Holder | Shares | % |
|---|---|---|
| Nirmal Bhanwarlal Jain | 93,07,632 | 19.85 |
| Madhu N. Jain (wife) | 27,67,524 | 5.90 |
| Venkataraman Rajamani | 25,84,594 | 5.51 |
| Aditi Avinash Athavankar (wife of R.V.; trustee Kalki Family Pvt Trust) | 14,40,000 | 3.07 |
| Ardent Impex Pvt Ltd (SBO Nirmal & Madhu Jain) | 5,76,429 | 1.23 |
| Orpheus Trading Pvt Ltd | 2,77,540 | 0.59 |
| Jain Mansukhlal (trustee, Nirmal Madhu Family Pvt Trust) | 80,059 | 0.17 |
| Harshita Nirmal Jain (daughter) | 55,615 | 0.12 |
| Aditi Athavankar (2nd folio) | 24,000 | 0.05 |
| Promoter group | 1,71,13,393 | 36.50 |
| Relatives classified as public | 3,61,619 | 0.77 |
- Nirmal Jain — founded IIFL (India Infoline, 1995); promoter/ED of IIFL Finance, promoter of IIFL Capital Services, NED of IIFL Home Finance. Not on 5paisa's board. Promoter group holds 24.89% of IIFL Finance and 30.70% of IIFL Capital. Reported IIM-A, CA, ex-Hindustan Lever UNVERIFIED.
- R. Venkataraman — co-promoter; ED IIFL Finance, NED IIFL Home Finance. Reported IIT-KGP, IIM-B, ex-ICICI and Barclays UNVERIFIED.
- Group context UNVERIFIED: RBI gold-loan restriction on IIFL Finance (Mar–Sep 2024); SEBI onboarding bar on IIFL Securities (Jun-2023, SAT stay); group-wide IT search 28 Jan–3 Feb 2025 incl. 5paisa. Other related parties: MNJ Consultants, Sunder Bhanwar Ventures, India Infoline Employee Trust, Meenakshi Towers LLP, Shreyans Foundations LLP.
Promoter support and trading history
| Date | Event | Value |
|---|---|---|
| Dec-2017 | N. Jain market buy 1,28,520 sh | ~₹2.46 Cr |
| Dec-2018 / May-2019 | Market purchases | — |
| Aug-2019 | Rights: promoters took 49,32,734 sh | — |
| May-2021 | 12 lakh warrants at ₹500 (₹60 Cr); ₹45 Cr converted FY23 | ~₹15 Cr lapsed |
| Mar-2023 | N. Jain 1,25,000 sh; R.V. 75,000 sh | ~₹5.5 Cr |
| Jun-2023 | Family trust 15,000; R.V. 5,000 | — |
| 26–30 Dec 2025 | Harshita Jain 10,420 sh at ~₹335 | ₹34.9 lakh |
| 13 Apr 2026 | Rights: 68,72,275 sh (~133% of entitlement) | ~₹206 Cr |
Key management
| Person | Role | Since | Background | FY26 pay |
|---|---|---|---|---|
| Gaurav Seth (DIN 10415364) | MD & CEO | CEO 14 Jan, MD 17 Jan 2025 | ~25 yrs: CPO Syfe; founding CBO Paytm Money; Morgan Stanley WM digital (NY). CFA, ISB MBA, Thapar BE. 2,00,000 ESOPs; no shares | ₹2.26 Cr |
| Gourav Munjal (DIN 06360031), 38 | WTD & CFO | Board 16 Jan 2020 | B.Com, CA, CS, ACCA DipIFRS; ex-IIFL group finance. 9,656 sh + 1,75,000 ESOPs. Named officer in default in SEBI OBPP order; sold 29,700 sh Dec-2023 (~₹1.65 Cr) | ₹0.81 Cr (+16%) |
| Ameya Agnihotri (DIN 07680132) | WTD & CTO | Resigned eff. 30 Sep 2026 | Highest-paid director; ₹18 lakh sundry receivable from him at Mar-26; sold 12,500 sh Mar-2025 (₹41.6 lakh) | ₹2.31 Cr (+35%) |
| Mehul Somaiya (ACS 43026) | CS & Compliance Officer | 16 Jul 2026 | Ex-SBM Bank India, IIFL Finance, Tata Capital, L&T Financial | — |
| Yogesh Maroli / Lalit Lathe / Mahesh Gujaran | CISO / CRO / Chief Surveillance | — | Ops head Lalit Lathe; Risk Mandar Chavan | — |
| Mehul Jain; Rajeshree Jadhav; Dhruv Kapadia; Dinesh Singh; Geetha Menon | Trading products; digital sales; customer service; design; HR | Singh, Menon Jan-2026 | — | — |
Pay disclosures: AR median ratios (Seth 12.45x, Munjal 35.47x, Agnihotri 34.58x) are attached to the wrong names; all imply a median ~₹6.5 lakh, so the CEO ratio is ~35x Est.. Median pay +9%, managerial +4%. Executive pay ~₹5.4 Cr ≈ 12% of PAT. Other KMP: Namita Godbole (CS to 11 Jul 2025) ₹25.8 lakh; Charvi Panchmatia (CS from 10 Oct 2025) ₹7.0 lakh; ex-CEO Narayan Gangadhar ₹1.19 Cr in FY25. Headcount 721; 318 hires; voluntary attrition 32.6%; average age 31.1; women 30.9%.
Leadership-churn timeline
| Date | Event |
|---|---|
| Jun–Dec 2023 | Ex-CEO/WTD Prakarsh Gagdani sold ~5.5 lakh sh (>₹2.5 Cr, ~45 trades) |
| May-2023 | Narayan Gangadhar (ex-Angel One CEO) appointed CEO |
| 30 May 2024 | Gangadhar resigns eff. 28 Aug 2024 to become Strategic Advisor (AI) to IIFL group |
| 28 Aug 2024 – 14 Jan 2025 | No MD/CEO; LODR Reg 26A non-compliance flagged by secretarial auditor; Sep-24 and Dec-24 results certified by CFO alone |
| Jan-2025 | Gaurav Seth appointed |
| 11 Jul 2025 | CS & CCO Namita Godbole exits; interim CO Ravindra Kalvankar 23 Jul |
| 2 Sep 2025 | ID Ravindra Garikipati retires; Sudhendoo Ganddhi appointed CCO |
| 10 Oct 2025 | Charvi Panchmatia CS (seat vacant ~3 months) |
| 13 Jan 2026 | Abhinav Agarwal (product), Dinesh Singh (design), Geetha Menon (HR) hired |
| 13–17 Apr 2026 | Panchmatia resigns; CS vacant again to 16 Jul 2026 |
| 15–16 Jun 2026 | CCO Ganddhi resigns after ~9 months |
| 18 Jun 2026 | Board meeting postponed "until further notice" for "certain exigencies"; Giskard valuation report dated the same day; link UNVERIFIED; re-held 28 Jul |
| 18 Sep 2026 | Head – Investing Product Abhinav Agarwal resigns (~8 months) |
| 30 Sep 2026 | WTD & CTO Ameya Agnihotri resigns; no successor named |
Board of directors (13 Oct 2026)
| Name | Role | Category | Tenure | Background / other boards | FY26 attendance | FY26 pay |
|---|---|---|---|---|---|---|
| Dr Archana Hingorani (DIN 00028037) | Chair; RMC chair | Independent | Through FY25–26 | ID Mafatlal, Grindwell Norton, Phoenix Mills, Balaji Telefilms, EMA Partners (5 listed); ex-CEO IL&FS Investment Managers; PhD Pittsburgh | 7/7 | ₹6.0L + ₹10.45L |
| Milin Mehta (DIN 01297508) | Audit Committee chair | Independent | n.d. | ID VA Tech Wabag, Styrenix, Atlanta Electricals; CA, lawyer | 7/7 | ₹6.0L + ₹10.25L |
| Nirali Sanghi (DIN 00319389) | SRC chair | Independent | n.d. | Founder-CEO India Parenting; ex-Barings, Citi, BCG | 6/7 | ₹6.0L + ₹7.95L |
| Dr Sarat Kumar Malik (DIN 09791314) | ESG chair | Independent | 8 Jul 2025–7 Jul 2030 | ID String Metaverse, Spacenet; ex-SEBI/RBI | 6/6 | ₹5.30L |
| Zor Gorelov (DIN 11329941) | ID Committee chair | Independent | 9 Oct 2025–8 Oct 2030 (99.996% vote) | Ex-CEO Kasisto (US AI banking); Klaros | — | ₹4.15L |
| Gaurav Seth | MD & CEO | Executive | Jan-2025 | — | 7/7 | ₹2.26 Cr |
| Gourav Munjal | WTD & CFO | Executive | Jan-2020; re-appointed 1 Sep 2026 AGM | Director of all 4 subsidiaries | 7/7 | ₹0.81 Cr |
| Ameya Agnihotri | WTD & CTO | Executive | Ceased 30 Sep 2026 | — | 7/7 | ₹2.31 Cr |
| Ravindra Garikipati | ID | Independent | Ceased 2 Sep 2025 | — | 1/2 | ₹2.1L |
7 board meetings FY26 (1 May, 8 Jul, 9 Oct 2025; 13 Jan, 21 Jan, 24 Feb, 11 Mar 2026). ID fees ₹75,000/board or audit meeting, ₹20,000 other committees, ₹6 lakh commission; IDs hold no shares/ESOPs; FY27 NED commission up to 1% of profit approved. Committees: Audit, NRC, SRC, Finance, RMC, CSR, ESG, ID, IT. No promoter or Fairfax director.
Shareholding trend
| Quarter | Promoter | FII/FPI | DII | Public | # holders |
|---|---|---|---|---|---|
| Dec-24 | 32.76 | 21.59 | 0.25 | 45.38 | 58,385 |
| Mar-25 | 32.75 | 21.57 | 0.25 | 45.41 | 58,095 |
| Jun-25 | 32.75 | 21.62 | 0.26 | 45.37 | 56,884 |
| Sep-25 | 32.74 | 21.68 | 0.25 | 45.32 | 55,170 |
| Dec-25 | 32.78 | 12.36 | 0.01 | 54.83 | 55,308 |
| Mar-26 | 32.76 | 12.41 | 0.01 | 54.80 | 52,243 |
| Jun-26 (post-rights) | 36.50 | 15.11 | 0.00 | 48.38 | 50,145 |
| Sep-26 | 36.50 | 15.21 (20 FPIs) | 0.00 | 48.27 | 47,099 |
| Pro-forma post swap, swap only Est. | 34.97 | — | — | 65.03 | — |
| Pro-forma fully diluted incl. ESOPs (filing 9 Oct 2026) Fact | 34.53 | — | — | 65.47 | — |
Dec-25 FII drop = Ward Ferry exit (WF Asian Reconnaissance/Smaller Cos, 7.88%) with Madhusudan Kela's Shubhi Consultancy (domestic LLP, counted as public) buying — not an unexplained exodus (ScanX "19.91% → 17.88%" is a misprint). At Mar-26, 67 holders owned 83% of equity. Rights take-up Est.: promoters ~68.7 lakh vs ~51 lakh entitlement; FIIs ~13 lakh extra; non-institutional ~30 lakh under-subscribed.
Named large holders and the Fairfax reconciliation
| Holder | Jun/Sep-26 % | Class | Note |
|---|---|---|---|
| Promoter group | 36.50 | Promoter | Nil pledge |
| FIH Mauritius Investments (Fairfax / Prem Watsa) | 24.54 | Public, foreign company | 76,70,130 sh at Mar-26 (24.5%); 24.55% Sep-25; added ₹44.9 Cr at ₹500 (2021) |
| HWIC Asia Fund Class A (Fairfax) | 8.22 | FPI Cat-I | 38,55,279 sh (25,70,186 at Mar-26 → full rights take-up) |
| Fairfax (FIH + HWIC) — figure used | 32.76 | CRISIL: 32.82% (Jun-24), 32.80% (Dec-24), 32.78% (Jun-25), 32.76% — flat | |
| RIMCO India Ltd (Fairfax-affiliated per governance input; background not verified per street input) | 2.73 | FPI Cat-II | 2021 preferential participant |
| Fairfax incl. RIMCO — alternative | ~35.49 | Apparent "+2.7pp" vs CRISIL series is definitional (RIMCO added), not buying | |
| Shubhi Consultancy Services LLP (+PAC Brijkishor Trading) — Madhusudan Kela-linked (reported) | 7.46 | Public LLP | 23.31 lakh sh 17–19 Nov 2025 at ~₹290–293 (~₹68 Cr); took rights |
| Bank Muscat India Fund | 3.98 | FPI Cat-II | Up from ~3.2% (timing unverified) |
| Amber Pabreja / Devi Yeshodharan | 2.42 / 1.77 (post-swap) | Public | Pending swap shares |
| Retail <₹2 lakh (48,620 holders) | 10.43 | Public | True dispersed float ~16% Est. |
| MF / insurance / DII | 0.00 | — | Zero domestic institutions |
Insider / SAST disclosures
| Date | Person | Category | Action | Qty | Value |
|---|---|---|---|---|---|
| 13 Apr 2026 (disclosed 13 May) | Nirmal Jain & PACs | Promoter | Rights allotment (SAST 29(2)) | 68,72,275 | ~₹206 Cr |
| 26–30 Dec 2025 | Harshita Nirmal Jain | Promoter group | Buy | 10,420 | ₹34.9 lakh |
| 17–19 Nov 2025 | Shubhi Consultancy LLP + Brijkishor | Acquirer >5% | Buy (SAST 29(1)) | 23,31,000 | ~₹68 Cr |
| 4–25 Nov 2025 | WF Asian funds (Ward Ferry) | Exiting holder | Sell 11,874 then 24,21,905 | 24,33,779 | ~42% loss vs ₹500 cost |
| 4–5 Mar 2025 | Ameya Agnihotri | WTD/CTO | Sell (to nil) | 12,500 | ₹41.6 lakh |
| Mar 2025 | Sapna Kshirsagar | Designated person | Sell | 900 | — |
| Dec 2023 | Gourav Munjal | WTD/CFO | Sell | 29,700 | ₹1.65 Cr |
| Jun–Dec 2023 | Prakarsh Gagdani | Ex-CEO | ~45 sells | ~5.5 lakh | >₹2.5 Cr |
| Oct–Dec 2023 | Mayur Dedhia | Designated person | Sells | ~36,000 | ~₹1.9 Cr |
| Mar & Jun 2023 | N. Jain, R.V., family trust | Promoter | Buys | 2.2 lakh | ~₹6.4 Cr |
Promoters buy; EDs and KMP net sell. Caveat: Trendlyne (insider data source) is owned by Giskard, the acquisition target.
Bulk / block deals
| Date | Exch | Party | B/S | Qty | Price ₹ |
|---|---|---|---|---|---|
| 17 Nov 2025 | BSE | WF Asia Fund (Ward Ferry) | Sell | 24,21,905 | 289.16 |
| 17 Nov 2025 | BSE | Shubhi Consultancy LLP (Kela) | Buy | 19,12,362 | 290.69 |
| 17 Nov 2025 | NSE | Shubhi Consultancy LLP | Buy | 3,03,301 | 292.94 |
| 17 Nov 2025 | BSE | Bhavin Yashodhan Mehta | Buy/Sell | 7,06,838 each | 289.16/289.30 |
| 17 Nov 2025 | BSE | Neo Apex Venture LLP | Buy/Sell | 7,37,159/7,27,159 | 289.59/291.09 |
| 17 Nov 2025 | BSE | D3 Stock Vision LLP | Net buy | ~1.35 lakh | 289.55/293.18 |
| 17 Nov 2025 | BSE | Vedika Vanijya | Net buy | ~0.84 lakh | 289.28/292.93 |
| 17–18 Nov 2025 | BSE/NSE | Irage, NK Securities, Junomoneta, Microcurves | HFT round trips | ~1.8–2.1 lakh legs | 294–355 |
| 10 Oct 2025 | NSE/BSE | Graviton, Irage, NK Securities, Pace, Silverleaf | HFT round trips | 2.2–3.6 lakh | 358–367 |
No bulk/block deals in 2026. Stock rose ~21% in two days after the Kela entry and ~15% (to ₹397 intraday) after Q2 FY26 results.
Related-party transactions — actual FY26 (AR Note 34, ₹ Cr)
| Counterparty | Nature | FY26 | FY25 |
|---|---|---|---|
| IIFL Facilities Services | Rent, IIFL House (registered office) | 2.09 | 2.21 |
| IIFL Facilities Services | Expense allocation paid | 1.32 | 1.51 |
| IIFL Finance | Allocation paid / received | 1.24 / 0.49 | 1.63 / 0.45 |
| IIFL Capital Services | Allocation paid / received | 0.91 / 0.34 | 2.18 / 1.58 |
| IIFL Home Finance; Livlong Protection | Allocation received | 0.06; 0.24 | 0.01; — |
| IIFL Management Services | Rent | 0.01 | 0.02 |
| India Infoline Foundation | CSR (all FY26 CSR) | 1.46 | 0.98 |
| KMP remuneration | Seth 2.26; Agnihotri 2.32; Munjal 0.81; Godbole 0.26; Panchmatia 0.07 | 5.71 | 4.80 |
| ID sitting fees | — | 0.65 | 0.59 |
| Ameya Agnihotri | Sundry receivable from director | 0.18 | — |
| Gross IIFL-group flows paid (rent + allocations + others + CSR) | ~2.2% of revenue | ~7.1 | ~8.6 |
Balances: security deposit with IIFL Facilities ₹0.98 Cr; payables to group ₹1.08 Cr. No ICDs, loans or guarantees with any IIFL entity in FY25 or FY26 (Note 15 nil; CARO 3(iii) nil to related parties). Note 34 covers "significant" transactions. Aug-2025 AGM also approved "material" RPTs not visible in the notes (open question). No brokerage/referral income from IIFL entities disclosed.
FY27 omnibus RPT approvals (AGM 1 Sep 2026; ICDs taken or given at SBI 1-yr MCLR + 250–350 bp, <1 yr)
| Counterparty | Relation | Cap ₹ Cr | % of FY26 turnover | Counterparty FY26 PAT ₹ Cr |
|---|---|---|---|---|
| IIFL Finance | Common promoters (24.89%) | 830 | 231% | 1,153.5 |
| IIFL Facilities Services | WOS of IIFL Capital | 725 | 201% | 75.8 |
| IIFL Home Finance | Sub of IIFL Finance | 720 | 200% | 745.8 |
| IIFL Samasta Finance | Sub of IIFL Finance | 716.5 | 199% | 21.3 |
| IIFL Management Services | WOS of IIFL Capital | 216.5 | 60% | -9.2 (loss) |
| Livlong Insurance Brokers | WOS of IIFL Capital | 216 | 60% | 6.8 |
| Livlong Protection & Wellness | Sub of IIFL Capital | 66 | 18% | 9.8 |
| IIFL Capital Services | Common promoters (30.70%) | 43 | 12% | 530.9 |
| IIFL Commodities (non-operational) | WOS of IIFL Capital | 16 | 4% | 4.4 |
| IIFL Fintech | WOS of IIFL Finance | 14.5 | 4% | 2.7 |
| IIHFL Sales | Step-down of IIFL Finance | 14.5 | 4% | 1.6 |
| India Infoline Foundation (Sec 8) | WOS of IIFL Capital | 2.5 | 1% | -27.0 |
| Total | 12 entities | ~3,580 | ~11x revenue |
Caps ~500x actual flows; allow ICDs given to loss-making entities after net worth rose to ~₹1,130 Cr. Nothing drawn — optionality, not leakage. All passed 99.99%. Monitor the H1 FY27 Reg 23(9) filing.
Auditor
| Item | Detail |
|---|---|
| Statutory auditor | V. Sankar Aiyar & Co. (FRN 109208W), Mumbai; partner Asha Patel (M.No. 166048); UDIN 26166048RJEBRB7425 |
| Tenure | ~FY18 onwards; second and final 5-yr term from 15th AGM (2022) to 20th AGM (2027): rotation due 2027 |
| Fees FY26 | Audit ₹17.5 lakh + certification ₹2.5 lakh = ₹20 lakh |
| FY26 opinion (signed 30 Apr 2026) | Unmodified. EoM (Note 42): only the uncertain outcome of the Jan-2025 IT search — "not received any communication… impact not ascertainable". Does not cover the ₹33.02 Cr order (5 May 2026) |
| Q1 FY27 limited review (16 Jul 2026) | Unmodified; EoM names the ₹33.02 Cr s.158BC(1)(c) demand (block 1 Apr 2018–3 Feb 2025), appeal at CIT(A); Other Matter: one subsidiary reviewed by another auditor |
| KAM | One: IT systems and controls over financial reporting |
| IFC opinion | Unmodified ("adequate", "operating effectively"); covers financial reporting only — not in conflict with NSE operational findings, but in tension with them |
| CARO | Clean; MTF repayable on demand (standard wording); no fraud (s.143(12)); no whistle-blower complaints; audit trail operational |
| Others | Internal: ANSA & Associates LLP; Secretarial: Nilesh Shah & Associates (FY26–FY30); Scrutinizer: Shah Patel & Associates; RTA: MUFG Intime |
Subsidiaries and group structure
| Entity (all 100%) | Purpose / status | Contribution |
|---|---|---|
| 5paisa P2P Ltd | RBI NBFC-P2P (CoR N-13.02371) | Total assets ₹5.26 Cr; PAT ₹0.03 Cr |
| 5paisa Corporate Services Ltd (inc. 27 Oct 2018; ex-5paisa Insurance Brokers, renamed 16 Nov 2022) | Dormant: "shall commence its business shortly" | Nil |
| 5paisa Trading Ltd (inc. 27 Feb 2020) | — | Immaterial |
| 5paisa International Securities (IFSC) Ltd (inc. 15 Jun 2022) | GIFT City; still awaiting NSE IFSC membership after 4 years | Q1 FY27 income ₹3.75 lakh |
| Investment ₹7.85 Cr less ₹3.51 Cr impairment = ₹4.34 Cr | Combined turnover ~₹0.18 Cr | Consol PAT ₹44.19 vs standalone ₹44.12 Cr |
No associates, JVs or cross-holdings. SEBI advisory (Dec-2024): subsidiaries must not use the 5paisa brand for unregulated products. Track record on new businesses is weak: insurance arm dormant, IFSC unit not operational, IA business being exited, RA licence lapsed. Acquisition record: Giskard is the first.
Governance red flags
- Leadership and compliance-function instability (above).
- Unexplained 18 Jun 2026 board postponement.
- NSE QSB warning on "systemic weaknesses" plus 83 actions; board report says controls "adequate and effective".
- Tax exposure ~₹49–71 Cr.
- RPT approval mechanics (HWIC vote; ~11% unaffiliated).
- Giskard disclosure error; ~13x revenue; data-platform conflict.
- SEBI PFUTP finding naming the sitting CFO.
- Two near-equal blocks; zero DIIs.
- Disclosure quality: CL mis-addition, MD&A swap, pay ratios, BRSR "zero penalties", CP LoO "no regulatory strictures", ESOP count conflict (7.18 vs 2.45 lakh exercisable).
- Weak new-business record.
Supply Chain
For a broker, "suppliers" are regulated market rails, funding and technology; "customers" are retail traders and investors.
↑ Upstream — what 5paisa depends on
| Input | Named suppliers / counterparties | Dependence and risk | Pass-through |
|---|---|---|---|
| Market access & clearing | NSE, BSE, MCX; NSE Clearing, ICCL, MCXCCL INFERRED | Regulated near-monopoly; NSE dominates F&O — effectively single-source | Transaction charges, SEBI fees, STT, stamp passed through; rebate income removed by true-to-label (Oct-2024) |
| Depository | CDSL only (no NSDL) | Single depository | DP ₹15.34/scrip/day on sell; BSDA AMC ₹25/month |
| Funding for MTF and margin | SBM, HDFC, Indian, Bandhan, DCB, Federal (OD/WCDL vs FD); Aditya Birla Finance, IDFC First (WCDL vs receivables); IDBI BG ₹75 Cr; CP ₹400 Cr limit (ICICI IPA) | ~9 lenders; borrowings ₹378.6 Cr Mar-26; unutilised ₹366 Cr; tenors 7–365 days — rollover risk; RBI intraday ban from 1 Jul 2026 | MTF ~18% p.a. client price vs ~8.9% borrowing cost Est. |
| IIFL group support | IIFL Finance (CRISIL AA/Stable), IIFL Capital, 360 ONE WAM; promoters | ₹500 Cr ICD support line (undrawn); rating "centrally factors" support; shared premises and media staff | Rent ₹2.09 Cr; allocations |
| Technology | In-house; XTS APIs (Symphony Fintech INFERRED); TradingView; Google Cloud INFERRED; LLM for MCP; exchange co-location | Moderate lock-in on OMS/RMS; outages bring penalties (MCX ₹2.60 Cr for unreported glitches) | Fixed cost |
| Content & partner products | smallcase, ClearTax, MarketSmith, Intraedge, Vested; Trendlyne (pending) | Non-critical | n/a |
| Customer acquisition | Digital ads (Google/Meta INFERRED), affiliates, referrals, partner/sub-broker model | CAC sensitive to ad costs and SEBI incentive curbs | Not passed through |
| People | 721 staff; ~200+ in tech | 32.6% attrition; CTO exit | ~₹115 Cr gross annual cost Est. |
Import/country dependence negligible; cloud and LLM vendors may be foreign-headquartered. Supplier concentration is highest in regulated rails (NSE, CDSL, RBI-regulated banks).
↓ Downstream — who depends on 5paisa
| Dimension | Detail |
|---|---|
| End customers | Indian retail individuals: DIY investors and high-volume traders; no institutional broking |
| Scale | 52.6 lakh registered; ~3.3 lakh NSE-active; ~14,500 MTF borrowers Est.; 13.68 lakh active SIPs |
| Geography / age | ~75% Tier 2/3 (call); 92% of FY26 adds from Tier 2/3; 62% under 35 |
| Customer concentration | None disclosed or likely |
| Product concentration | Brokerage 45–49% of revenue, ~80% derivatives (Jul-25); MTF >₹5L cohort 10.6% of borrowers but likely a large share of book |
| What output ends up in | Executed trades; holdings in CDSL demat; MF units via RTAs; MTF positions pledged to 5paisa; US stocks via Vested |
| Stickiness / tenor | At-will, no contracts; switching cost low; stickiness from pledges, MTF ("older customers… trust your platform"), API/algo integrations, SIP mandates |
Value-chain map
| Link | Pricing power | Why |
|---|---|---|
| Exchanges (NSE above all) | Strongest | Set charges and product design; true-to-label removed broker rebates |
| SEBI / RBI | Strong | Define economics: F&O framework, incentive curbs, 1 Jul 2026 intraday ban |
| Scale discount brokers (Groww, Zerodha, Angel) | Sets price cap | ₹20 or zero pricing is the industry ceiling |
| 5paisa | Weak in brokerage Moderate in funding | Price-taker; MTF spread healthy on granular book; edge is features, not price |
| Clients | High | Low switching cost, multi-homing |
Competitive Position
Rank #17 by NSE active clients (Jul-26), below sister broker IIFL Capital (#16). Oligopoly at the top, fragmented tail.
Market share — three numbers, one reconciled view
| Measure | Value | Source / label | Comment |
|---|---|---|---|
| Overall market share FY26 (used) | 0.63% | CRISIL 25 Aug 2026 Fact | Cash ~0.5%, F&O ~0.6%; FY22 cash 1.3%, F&O 1.6%; FY23 1.2%, FY24 1.0%, FY25 0.72%. Below 0.75% downgrade trigger |
| Share of NSE active clients, Jul-26 | ~0.73% | 3.31 lakh / ~4.54 Cr Est. | ~0.85% Mar-25; ~0.72% Mar-26 |
| Management claim (Q4 FY26 call) | ~2% | CEO UNVERIFIED | No basis given; possibly retail F&O premium ADTO (₹1,336 Cr / ₹78,000 Cr ≈ 1.7%, derived). Not used |
| ValuePickr Dec-2024 ranking | 1.28% | Forum | 13th; stale |
Peer comparison
| Company | Status | FY26 Rev ₹ Cr | YoY | EBITDA % | PAT ₹ Cr | PAT % | RoE | P/E | P/B | EV/EBITDA | NSE actives (share) | Moat |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5paisa | Listed | 320 (TI) | -11.1% | 31.6% (Q1 FY27 29.5%) | 44 | 13.8% | 7.1% | 36.8x | 1.44x | n.m. | 3.31 lakh (0.73%, #17) | Weak |
| Groww (Billionbrains) | Listed Nov-25 | 4,644.6 | +19.0% | ~61–63% | 2,083 | 44.8% | ~25% | 49.5x | 12.5x | n.m. | 1.34 Cr (29.2%, #1) | Strong |
| Zerodha | Unlisted | ~8,847 | ~0% | n.d. | 4,283 | ~48.4% | Very high | n.a. | n.a. | n.a. | 67.91 lakh (14.7%, #2) | Strong |
| Angel One | Listed | 5,136.6 | -1.9% | n.d. | 915.1 | 17.8% | ~15% | 26.4x | 4.4x | n.m. | 67.55 lakh (14.7%, #3) | Mod-strong |
| ICICI Securities | Delisted (ICICI Bank sub) | 5,890 | -7.0% | n.d. | 1,713 | 29.1% | n.d. | n.a. | n.a. | n.a. | 21.60 lakh (4.7%, #4) | Strong |
| Upstox (RKSV) | Unlisted | 945 (FY25) | -0.6% | ~1% | 215 (FY25) | 17.8% of TI | n.d. | n.a. | n.a. | n.a. | 18.54 lakh (4.0%, #5) | Moderate |
| Motilal Oswal | Listed | 5,908 (net op.) | +14% | n.d. | 2,043 / 2,360 op. | 34.6% | n.d. | ~31.7x | n.d. | n.m. | 9.02 lakh (~2.0%, #11) | Strong |
| Kotak Securities | Unlisted | n.d. | n.d. | n.d. | ~465 (Q1 FY26) | n.d. | n.d. | n.a. | n.a. | n.a. | 13.92 lakh (3.0%, #6) | Strong |
| Dhan (Raise) | Unlisted | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.a. | n.a. | n.a. | 11.21 lakh (2.4%, #8) | Moderate |
| Paytm Money | Sub of One97 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.a. | n.a. | n.a. | 7.63 lakh (1.7%) | Weak-mod |
Prices: Groww ₹193.81, mcap ₹1,20,673 Cr (13 Oct 2026); Angel ₹294.80, ~₹27,250 Cr (8 Oct); MOFSL ~₹64,826 Cr (7 Oct). EV/EBITDA n.m. for brokers. Revenue definitions differ (total income vs net op. revenue). Profit pool: Zerodha + Groww + Angel ≈ ₹7,280 Cr FY26 PAT; 5paisa ≈ 0.6%.
NSE active clients — top brokers (Sep-26) and 5paisa's neighbourhood (Jul-26)
| Rank | Broker | Active clients | MoM | Share |
|---|---|---|---|---|
| 1 | Groww | 1.34 Cr | +1,00,961 | 29.16% |
| 2 | Zerodha | 67.91 lakh | -5,313 | 14.73% |
| 3 | Angel One | 67.55 lakh | +36,956 | 14.65% |
| 4 | ICICI Securities | 21.60 lakh | +4,410 | 4.69% |
| 5 | Upstox | 18.54 lakh | -10,343 | 4.02% |
| 6 | Kotak Securities | 13.92 lakh | n.d. | 3.02% |
| 7 | HDFC Securities | 13.54 lakh | n.d. | 2.94% |
| 8 | Dhan | 11.21 lakh | +13,624 | 2.43% |
| 9 | SBI Securities | 10.21 lakh | -22,525 | 2.21% |
| 10 | Paytm Money | 7.63 lakh | -27,950 | 1.66% |
| — | INDmoney / Sahi | 7.19 / 2.81 lakh | +5,070 / +28,077 | 1.56% / 0.61% |
| 11–15 (Jul) | Motilal 9,01,868; Paytm 8,61,706; INDstocks 6,93,526; Sharekhan 5,30,958; Axis Sec 4,28,671 | — | — | — |
| 16 (Jul) | IIFL Capital Services (sister) | 3,41,109 | — | ~0.75% |
| 17 (Jul) | 5paisa | 3,31,486 | — | ~0.73% |
| 18–22 (Jul) | Choice 2,50,748; Mirae 2,32,231; Geojit 2,16,303; PhonePe Wealth 2,13,303; Fyers 2,00,810 | — | — | — |
Industry: NSE actives 4.92 Cr (Mar-25) → 4.57 Cr (Mar-26, -7%) → 4.61 Cr (Sep-26); Groww took >63% of Sep-26 net adds. FY26 share changes: Groww 26.26→28.31%; Zerodha 16.03→15.08%; Angel 15.4→14.79%; Upstox 5.58→4.35%; ICICI Sec 3.96→4.57%; SBI Sec 1.99→2.55%; Dhan 2.27%; Kotak ~3.03%. Groww retail cash ADTO 15.7% (Q4 FY26); Motilal blended ADTO 7.8%; Zerodha MTF book ~₹9,000 Cr; Groww MTF ₹2,814 Cr.
5paisa vs each peer
| Peer | 5paisa strengths | 5paisa weaknesses |
|---|---|---|
| Groww | P/B 1.44x vs 12.5x; F&O-trader heritage | ~40x smaller active base; PAT margin 13.8% vs 44.8%; revenue -11% vs +19%; MF AUM ₹2,073 Cr vs ₹1.9 lakh Cr |
| Zerodha | Listed, rated balance sheet | ~20x smaller actives; PAT ~100x larger; MTF book ~21x 5paisa's funding book |
| Angel One | Lower P/B; flat-fee simplicity | PAT 21x larger; 3.74 Cr clients; AMC/wealth/credit diversification |
| ICICI Sec / Kotak Sec | Pure digital cost base | Bank-led 3-in-1 distribution, captive bases, gaining share |
| Upstox | Profitable; lower ad burn | ~5.6x the actives; stronger backers (Tiger, Ratan Tata) |
| Motilal Oswal | Lower-cost model for traders | 77% non-broking income; research brand |
| Dhan | Larger registered base; listed | ~3.4x actives and gaining; better trader product reputation |
| Paytm Money | A+ balance sheet | ~2.3x actives |
| IIFL Capital (sister) | Discount-pricing focus | Slightly more actives; group channel overlap |
Porter's Five Forces
| Force | Intensity | Comment |
|---|---|---|
| Rivalry | Very high | Price ~₹20/order or zero; top 3 hold ~58.5% of actives; 30+ tail brokers |
| New entrants | High | PhonePe Wealth, Sahi, INDmoney, Jio-BlackRock UNVERIFIED, Kotak Neo zero plans |
| Buyer power | High | Low switching cost; multi-homing |
| Supplier power | Mod-high | NSE near-monopoly in F&O; SEBI "licence to operate" |
| Substitutes | Moderate | Direct MF platforms, bank 3-in-1, PMS, passive |
Barriers to entry low-to-moderate and rising (compliance, cyber, algo rules); CAC is the real barrier (Upstox ₹467 Cr ads = 47% of FY25 expenses). Moat: weak — the IIFL lineage and A+ rating are a balance-sheet buffer, not a moat. No PLI/subsidy; tailwinds are financialisation, UPI/AA onboarding, T+1/T+0.
Regulatory timeline
| Date | Measure | Impact |
|---|---|---|
| 2024 (RBI) | Currency derivatives need underlying exposure | INR F&O volumes -~90% |
| Eff. 1 Oct 2024 | SEBI true-to-label MII charges | Rebate income gone (Zerodha ₹400 Cr → 0); key cause of broking & allied ₹229 → ₹181 Cr |
| Eff. 1 Oct 2024 | STT options 0.0625% → 0.1%; futures 0.0125% → 0.02% UNVERIFIED | Lower churn |
| 20 Nov 2024 / 1 Feb / 1 Apr 2025 | SEBI/HO/MRD/TPD/P/CIR/2024/132: lot size ₹15–20 lakh, one weekly expiry per exchange, +2% ELM, upfront premium, no calendar-spread benefit, intraday position monitoring | Cut retail F&O; exchange F&O ADTO ₹537 tn (Sep-24) → ₹288 tn (Feb-25) → ₹592 tn (Jan-26) → ~₹486–492 tn (Apr–Jun 26) |
| Feb 2025 | Retail algo framework UNVERIFIED | Cost; opportunity for API brokers |
| 2025 | Expiry days moved; delta-based OI limits UNVERIFIED | Fewer expiry-day trades |
| Jul 2025 | SEBI study: ~91% of F&O traders lost money FY25 (~₹1.06 lakh Cr) UNVERIFIED | Continued intent to curb |
| Feb 2026 Budget | Further STT rise reported (futures 0.05%, options 0.15%) UNVERIFIED | Further headwind |
| 2025–26 | Curbs on broker incentives, finfluencer rules; proposed RA restriction | Cited by CRISIL for active-client drop |
| 1 Jul 2026 (RBI) | No bank intraday facilities to brokers | ₹227 Cr of rights cash to exchange margin |
Risks & Red Flags
Risk register
| # | Risk | Category | Severity | Explanation | Mitigant |
|---|---|---|---|---|---|
| 1 | Continued loss of active clients and share | Business | High | Actives 4.2 → 3.3 lakh in FY26 (-21%); rank #17; Q1 FY27 new adds -28% QoQ | Growth marketing from rights; revamp; Trendlyne AI |
| 2 | CRISIL downgrade trigger breached | Financial | High | 0.63% vs 0.75% trigger; downgrade would raise CP/WCDL cost as MTF scales | NW ₹1,130 Cr; gearing 0.3x; IIFL support |
| 3 | Retail F&O regulatory tightening | Regulatory | High | ~80% of revenue derivatives (Jul-25); industry activity -20–30% | Shift to MTF, MF, T+5 |
| 4 | Rebate income loss (true-to-label) | Regulatory | High | Permanent; broking & allied -21% FY26 | In base |
| 5 | Negative operating leverage | Financial | High | Cost-to-income 73% → 79% → 81%; Q1 FY27 PAT +0.2% on income +14% | Employee cost -13% QoQ (partly capitalisation) |
| 6 | RoE dilution from over-capitalisation | Financial | Med-High | NW +74%; RoNW 5–7%; share count +50% | MTF deployment |
| 7 | Giskard valuation, governance, execution | Governance | Med-High | ~₹207 Cr, ~13x revenue, profit undisclosed; single DCF; undisclosed cash sellers; ex-IIFL associate; SEBI approval pending; promoter-purchase line retracted | Registered valuer; 99.99% vote |
| 8 | Income-tax block assessment ₹33.02 Cr (5 May 2026) | Tax | High | ~75% of FY26 PAT; unprovided; outside AR; plus ₹21.85 Cr AY24 (may overlap) | CIT(A) appeal; management "confident" |
| 9 | GST SCN ₹15.31 Cr (30 Sep 2026) | Tax | Med | FY23 ITC: excess ₹2.04 Cr, ineligible ₹0.07 Cr, reversal ₹13.20 Cr + interest/penalty | Company says "no merits" |
| 10 | Fairfax monetisation overhang | Governance/Market | High | 32.76% passive holder; Fairfax restructuring India stakes (51% of IIFL Capital, May-2026; IIFL Finance selldowns) | Promoter/Kela floor ~₹290–300 |
| 11 | IIFL linkage change | Governance | Med | Rating trigger on change in IIFL support/holding | Promoter stake up to 36.5% |
| 12 | Control-environment failures | Regulatory | High | 83 actions FY26; NSE QSB "systemic weaknesses"; MCX ₹2.60 Cr + 14-day bar; Mar-24 onboarding bar; SEBI PFUTP | New CS/CO; QSB remediation |
| 13 | Key-person churn | Execution | High | CTO, CCO, product head, 3 CSs, 3 CEOs | Promoter oversight |
| 14 | RPT headroom ~₹3,580 Cr incl. ICDs given | Governance | Med | Allows lending to loss-making group cos | Nil drawn; Reg 23(9) monitoring |
| 15 | Interest-rate / float dependence | Macro | Med | FD interest 29% of revenue; finance cost +37% FY26 | Rights equity reduces borrowing |
| 16 | MTF credit risk | Financial | Med | Limits up to ₹25 Cr/client; book growing fast | Granular (70.7% <₹1L); 0.01x bad debts |
| 17 | Market cyclicality | Macro | High | Volume-linked earnings | Recurring MTF/MF income |
| 18 | Price war | Business | Med-High | Zero-brokerage plans; funded entrants | Low cost base |
| 19 | Tech outages / cyber | Execution | Med | MCX penalty for glitches; third glitch Oct-2025 | ISO 27001; revamp |
| 20 | Product obsolescence | Business | Med | ~6% activation | AI features |
| 21 | Capital allocation / further M&A | Execution | Med | "Selective inorganic"; Giskard cash exceeds GCP bucket | Shareholder approvals |
| 22 | Disclosure quality | Governance | Med | Multiple AR errors and contradictions (table below) | Auditor rotation 2027 |
| 23 | Illiquidity, no dividend, zero DIIs | Market | Low-Med | ~29k shares traded 13 Oct; 2-yr return -26.6%; holders -19% since Dec-24 | — |
| 24 | ESG / conduct | ESG | Med | F&O promotion; bond mis-selling finding | SEBI ad norms |
| 25 | SEBI RA proposal | Regulatory | Med | RAs barred from researching distributed products — complicates broker + Trendlyne | Pending |
| 26 | Civil suit ₹2.70 Cr (Aravind Tambad) | Legal | Low | Ex-employee termination claim | Defended |
Red-flag checklist
| Flag | Status | Evidence |
|---|---|---|
| Rising debt | Moderate | ₹217 → ₹379 Cr FY26; CP limit ₹400 Cr; gearing 0.30x post-rights |
| Margin deterioration | Yes | EBITDA margin 35.4% → 31.6%; Q1 FY27 -292 bps YoY |
| Auditor concerns | EoM | EoM on IT search (FY26) and ₹33.02 Cr demand (Q1 FY27); KAM IT systems; opinions unmodified |
| Related-party abuse | Watch | No ICDs; ~₹3,580 Cr caps; HWIC vote; Giskard ex-IIFL associate |
| Promoter selling | No | Buying; 32.76% → 36.50% |
| Dilution | Yes | +50% rights; +4.4% swap |
| Customer loss | Yes | Actives -81% from FY22 peak |
| Litigation / tax | Yes | ~₹49–71 Cr |
| Institutional exit | Explained | Ward Ferry exit at loss; Kela bought; DIIs 0% |
| Rating trigger | Yes | 0.63% vs 0.75% |
| Earnings quality | Watch | Q1 FY27 capitalisation ₹7.22 Cr (~47% PBT) |
Regulatory, legal and enforcement log
| Date | Authority | Matter | Outcome |
|---|---|---|---|
| 14 Mar 2024 | MCX, then NSE/BSE | New-client onboarding restricted pending RCA | Revoked 15–17 Mar; Bombay HC writ/stay |
| 1 Jul 2024 | MCX MCSGFC | Non-reporting of glitches, delayed RCAs (inspection Apr-22 to Dec-23) | ₹2.5975 Cr + GST + 14-day bar; SAT stay 5 Jul 2024 on 50% deposit (₹1.30 Cr); fully provided; pending |
| 30 Jul 2024 | SEBI AO | Wrong UCC data for 14,494 clients (4.81%) | ₹2 lakh |
| 31 Oct 2024 | SEBI AO | Enhanced-supervision misreporting, client-balance gaps, AP supervision, MTF margin shortfall, cyber lapses | Penalty paid |
| FY25 | SEBI | KYC lapses | Administrative warning |
| 10 Sep 2025 | SEBI | RA registration expired | Surrendered; new RA 26 Feb 2026 |
| 13 Oct 2025 | SEBI AO (s.15HB) | OBPP: no seller agreements; ₹5.16 Cr not via RFQ; incomplete deal sheets; no risk policy; AT-1/Tier-II sold as "Bonds for Senior Citizens"/"Ultra Safe Bonds" (PFUTP) | ₹3 lakh joint & several on company, Munjal, Gangadhar; IDs exonerated |
| 19 Mar 2026 | SEBI | Links to algo platforms claiming guaranteed returns (one of 122 brokers) | Settled ₹1 lakh |
| 8 Jun 2026 | SEBI | IA registration unpaid fees | SCN; IA being surrendered |
| FY26 | NSE | MTF margin ₹72,542; T+5 breaches ₹50,000 ×2 (95 of 11,542 instances); 44-min incident delay ₹50,000; statements of accounts ₹1 lakh; payout delay ₹45,000 | Paid |
| FY26 | CDSL | VIPV/transmission irregularities (102 instances) | ₹4.62 lakh |
| 27 Oct 2025 | MCX | Third system glitch | ₹50,000 |
| FY26 | NSE (item 81) | QSB non-compliance: gaps in Risk, IT, Cyber, BCP, Wind-down; "systemic weaknesses in governance, reporting discipline, and internal control mechanisms" | Warning; item 83 directed before the Board |
| Oct-2024 to FY26 | NSE/BSE/MCX/CDSL | 83 actions; 23 with monetary penalties ~₹10.2 lakh | Frequency is the red flag |
Tax and disputed dues
| Item | ₹ Cr | Status | In AR? |
|---|---|---|---|
| IT block assessment s.158BC(1)(c), order 5 May 2026, block 1 Apr 2018–3 Feb 2025 (after 28 Jan–3 Feb 2025 search; s.158BC notice 6 Oct 2025) | 33.02 | CIT(A) appeal; Q1 FY27 EoM | No — post-dates AR; unprovided |
| IT reassessment AY2023-24 (order 23 May 2025; appeal date printed 9 Apr 2025 — typo) | 21.85 | CIT(A); contingent; may overlap block | Yes (Note 30) |
| IT AY2018-19 (order 1 Apr 2025) | 0.75 | Appeal filed 27 Apr 2026 | Yes |
| GST SCN FY23 ITC (CGST Mumbai East, 30 Sep 2026) | 15.31 | Contested | No |
| GST orders: Karnataka FY19 ₹0.52 Cr; Karnataka FY20 ₹0.10 Cr; Tamil Nadu FY22 ₹0.32 Cr | ~0.94 | Appeals filed / pending | Partly |
| Open exposure Est. | ~49–71 | 1.1–1.6x FY26 PAT; ~4–6% of NW, before interest/penalties | |
Disclosure-quality inconsistencies
| Document | Claim | Reality |
|---|---|---|
| AR Note 30 (standalone) | Contingent total ₹685.8 Cr | Components ₹625.8 Cr |
| AR MD&A | Finance cost ₹9.2 Cr, D&A ₹32.5 Cr; employee and finance costs "declined" | Swapped; both rose (+19.7%, +36.7%) |
| AR MD&A | "Consistent record of compliance without any reported deviations" | SEBI PFUTP order; 83 actions |
| BRSR | "Zero penalties or fines" | SEBI ₹3 lakh, exchange penalties |
| CP Letter of Offer (27 Jan 2026) | No material litigation or regulatory strictures in 5 years | MCX ₹2.60 Cr penalty, SEBI orders |
| AR remuneration annexure | Seth 12.45x median | ~35x; ratios on wrong names; Agnihotri increase 11% vs ~35% |
| AR p.4 pie | "Cross-sell & others 29%" | FD interest; cross-sell ₹1.06 Cr |
| AR ESOP | 7,18,400 exercisable (Note 35) | 2,44,950 vested (CG report) |
| AR MTF figures | ₹326 / ₹340 / ₹368 / ₹410 Cr | Different bases, loosely presented |
| Note 15 | Cross-refers RPT loans to "note 33" | Should be Note 34 |
Customer and street sentiment
| Platform | Rating | Themes |
|---|---|---|
| Apple App Store | 4.4/5 (386 ratings) | Easy trading; wrong P&L/holdings data; poor support; IPO mandate issues |
| Google Play | 4.3 (company deck); not independently retrieved | — |
| Trustpilot | 2.1/5 (9 reviews, 78% 1-star) | DP AMC on "free" accounts; auto square-off; re-KYC friction |
| ValuePickr (47 posts, ~14.3k views) | Bearish/disengaged | 2022 "customer service the worst"; 2024 red-flag questions; Aug-2026 "lagging peers" |
| Reddit / X | Not retrievable | Gap |
Concall Highlights & Guidance
AlphaStreet machine transcripts (preliminary), cross-checked with filings. Guidance is qualitative throughout. No sell-side participants identified.
| Quarter / call | Participants | Key numbers | Management said | Analyst Q&A / hidden risk | Tone |
|---|---|---|---|---|---|
| Q4 FY25 — 2 May 2025 | Seth only; Shah India Sec + 1 | Broking -23% QoQ; MTF income -11% (rate cut 1 Nov 2024); FY25 rev ₹360 Cr, PAT ₹68 Cr; adds ~91k; funding book ~₹260 Cr; MF AUM ₹1,392 Cr | "The market and our business will normalize over the next few quarters"; "Intra" AI tool "by early Q2" | ~22% revenue fall from F&O rules; traders migrating to MF | Defensive |
| Q1 FY26 — 10 Jul 2025 | Kajal Gandhi (ICICI Sec), Millennium Money, others | Income ₹77.8 Cr; PAT ₹11.5 Cr (-43%); fees -33.6%; employee +~50%; NW ₹616 Cr; ADTO ₹2.25 tn; book ₹312 Cr | "Top-three to top-five player in the next few years"; 3P cross-sell "The answer is no"; algo product "next couple of months"; MCP with Claude | Float interest (~₹70 Cr) ≈ annual profit; ~80/20 derivatives/cash; ~75% Tier 2/3; weekly-expiry risk dodged | Confident |
| Q2 FY26 — 10 Oct 2025 (transcript unreadable) | — | Income ₹77.3 Cr (-23%); PAT ₹9.48 Cr (-57%); H1 PAT ₹21.0 Cr (-50%); book ₹364 Cr; installs 22.7 Mn | Blamed volatility, FII selling; "quality acquisition"; Zor Gorelov joins | Stock +14–15% to ₹397 despite PAT fall | Macro-blaming |
| Q3 FY26 — 14 Jan 2026 | 44 attendees, zero questions | Revenue ₹79.4 Cr; broking ₹37.1 Cr (+7%); PAT ₹12.3 Cr; ADTO ₹3.31 tn; book ₹379 Cr; labour-code ₹0.62 Cr | Pay Later on 1,500+ stocks up to ₹3 Cr; onboarding upgrades | None | Upbeat |
| Q4 FY26 — 4 May 2026 | Seth, Munjal; RoboCapital, Talencia | Income ₹85.5 Cr (+20% YoY); PAT ₹10.9 Cr; F&O premium ADTO ₹1,336 Cr; adds >1 lakh; book ₹410 Cr | "Approximately 2% market share in both F&O and cash"; rights oversubscribed; margin capacity 1.5x | Macro: "Iran war", Brent >$100, indices -~11% | Defensive P&L / celebratory capital |
| Q1 FY27 — 17 Jul 2026 | Seth, Munjal; Jatin Sahani, Amit Mehendale (RoboCapital) | Income ₹88.4 Cr; PAT ₹11.6 Cr (+1%); adds -28% QoQ; book ₹422 Cr; MF ₹2,073 Cr | "From this quarter on, you can see an acceleration in growth"; operating leverage "very quickly"; rights: ₹227/₹150/₹88 Cr | Revenue "flat for about three years"; "biggest bet" is the revamp; "a little bit of moderation"; "some people have gained market share, some… lost" | Cautious / defensive |
| Q2 FY27 — 15 Oct (results), 16 Oct 2026 (call) | Pending: tests "acceleration" guidance and CEO letter's "MTF momentum to continue into FY27" | ||||
KPI trend from calls
| Quarter | Total income | Brokerage (AR) | PAT | OPM (Screener) | New clients | Base (lakh) | Funding book | MF AUM |
|---|---|---|---|---|---|---|---|---|
| Q1 FY25 | 102 | — | 20 | 36% | — | — | — | — |
| Q2 FY25 | 101 | — | 21.9 | 38% | — | — | — | — |
| Q3 FY25 | 85 | — | 16.2 | 35% | — | 47.4 | ~265 | — |
| Q4 FY25 | 71 | — | 10 | 30% | ~91k | 48.3 | ~260 | 1,392 |
| Q1 FY26 | 77.8 | 35.5 | 11.5 | 32% | ~80k | 49.1 | 312–315 | 1,573 |
| Q2 FY26 | 77.3 | 34.8 | 9.5 | 30% | 95k | 50.1 | 364–366 | — |
| Q3 FY26 | 79.4 | 37.1 | 12.3 | 34% | 78k | 50.8 | 379–380 | 1,868 |
| Q4 FY26 | 85.5 | 41.9 | 10.8 | 30% | >1 lakh | 51.8 | 410 | 1,761 |
| Q1 FY27 | 88.4 | 39.4 | 11.6 | 30% | 74k | 52.6 | 422 | 2,073 |
Guidance vs actual (credibility check)
| When | Said | What happened | Verdict |
|---|---|---|---|
| Q4 FY25 | Business will "normalize over the next few quarters" | Five quarters of ₹9.5–12.3 Cr PAT vs ₹20–22 Cr; FY26 PAT -35%; RoNW 11.9% → 7.1% → 5.2% | Missed |
| Q4 FY25 | "Intra" AI tool by early Q2 FY26 | Not referenced again; absent from AR | Faded |
| Q1 FY26 | Algo product "next couple of months" | AlgoSpace launched 20 Jun 2026 (~12 months) | Late |
| Q1 FY26 | Tech upgrade cycle ends "next few quarters" | Revamp still beta Jul-26; CTO resigned 30 Sep | Slipping |
| Q1 FY26 | "Top-three to top-five player" | Share 0.72% → 0.63%; rank #17 | Moving away |
| Q1 FY26 | 3P/insurance cross-sell: "no" | AR: "distribution-led offerings"; Jul-26 "midterm"; Giskard cites cross-sell | Reversal |
| Q4 FY26 | Rights money to fund growth | ₹227 Cr margin (RBI-forced), ₹150 Cr debt, ₹88 Cr GCP; then ₹121.6 Cr Giskard cash | Defensive |
| AR CEO letter | MTF momentum to continue into FY27 | Book ₹422 Cr, "much higher now"; limits ₹25 Cr | On track |
| Q4 FY25–Q1 FY27 | MF AUM growth | ₹1,392 → ₹2,073 Cr (+49%) | Delivered |
| Q1 FY27 | "Acceleration in growth" from Q2 | Test 15 Oct 2026; Q1 adds -28%, exits | Pending |
| Q1 FY27 | Operating leverage "very quickly" | Cost-to-income 81% even after ₹7.2 Cr capitalised | Not visible |
Credibility: low to moderate. Delivers on balance-sheet and feature items; repeatedly slips on P&L normalisation, share and platform timelines.
Contradictions and recurring themes
| Contradiction | Detail |
|---|---|
| Market share | "~2%" vs CRISIL 0.63% |
| Funding-book growth | "+10% QoQ" vs ₹410 → ₹422 Cr (+3%) |
| Rights total | "₹268 Cr" stated vs parts ₹465 Cr |
| Quality over quantity | Claimed every call; actives fall every year |
| 3P distribution | No (Jul-25) → distribution-led (Apr-26) → midterm (Jul-26) → cross-sell rationale (Giskard) |
| "Active customers" | Q2 FY26 write-up "5 Mn active" vs CRISIL ~4 lakh |
| AR MD&A | Cost declines that didn't happen; "second-largest discount broker"; "7% acquisition growth" is base growth |
| Giskard price | Item (g) cash ≤₹121.57 Cr vs item (h) "aggregate consideration"; promoter-purchase line withdrawn 29 Jul; corrigendum 21 Aug |
Recurring themes: regulation/macro as explanation; AI/product velocity (MCP, Intra, AlgoSpace, Scalper) with unquantified monetisation; mix shift to MTF/T+5/MF; RPC/LTV/CAC language without metrics; float income as hidden pillar. Tone path: defensive → confident → macro-blaming → upbeat (no Q&A) → defensive/celebratory → "reset rather than a setback" (AR) → cautious/defensive.
Growth, Outlook & Valuation
"Order book" equivalent — revenue visibility
| Bucket | Proxy | Size | Visibility |
|---|---|---|---|
| Annuity-like: MTF/T+5 interest | Avg funding book Q1 FY27 | ₹422 Cr | Medium (at-will, but sticky) |
| Annuity-like: float | Lien-marked FDs Mar-26 | ₹1,380 Cr | Rate-sensitive |
| Annuity-like: MF | AUM / active SIPs | ₹2,073 Cr / 13.68 lakh | Low yield |
| Transactional: brokerage | ~47% of FY26 revenue; ~80% derivatives | ₹149 Cr | Low |
| Contracted revenue | None | 0% | No order book; book-to-bill n.a. |
Growth plans and catalysts
| Horizon | Item | Status / timing |
|---|---|---|
| Near-term | Q2 FY27 results / call | 15 Oct / 16 Oct 2026 |
| Near-term | Giskard closing; SEBI RA change-of-control approval | ~Jan 2027 |
| Near-term | Complete platform revamp to production | "Next few months" (Jul-26); CTO replacement needed |
| Near-term | CTO successor; H1 Reg 23(9) RPT filing | Q3 FY27 |
| 12 months | MTF/T+5 scale-up (₹25 Cr limits; 2,500 T+5 scrips); NCDs up to ₹250 Cr/yr | Ongoing |
| 12 months | LAS, then NPS/LAMF; "couple of other things in the pipeline" | Unquantified |
| 12 months | CRISIL surveillance (trigger breached) | Aug-2027 review |
| 12 months | CIT(A) appeal on ₹33.02 Cr; GST SCN reply | Unknown |
| 3–5 years | AI-led investing platform (Trendlyne data, MCP, AlgoSpace); selective M&A | Strategic |
| Risk events | Fairfax stake decisions; further SEBI F&O/STT changes; auditor rotation 2027 | — |
No numeric guidance; no capex plans beyond tech (capex ₹7–19 Cr/yr). Industry tailwinds: financialisation, demat growth (~20 Cr+ UNVERIFIED), MTF industry book >₹1.1 lakh Cr. No PLI.
Valuation (CMP ₹347, 13 Oct 2026)
| Metric | Current | FY24 end | FY25 end | FY26 end | 3-yr avg |
|---|---|---|---|---|---|
| Price (₹) | 347 | 505.05 | 355.35 | 249.10 (ex-rights) | |
| Market cap (₹ Cr) | 1,627 | 1,575 | 1,110 | 779 | |
| P/E (TTM) | 36.8x | 28.9x | 16.3x | 17.6x | ~20.9x |
| P/B | 1.44x | 2.92x | 1.84x | 1.20x* | ~2.0x |
| EV/EBITDA | n.m. | n.m. | n.m. | n.m. | n.m. |
| Price / sales (TTM) | ~4.9x | 4.0x | 3.1x | 2.4x | |
| Earnings yield / dividend yield | 2.7% / 0% | 0% | 0% | 0% |
Implied requirement: to return to ~20.9x at ₹347 needs PAT ~₹78–80 Cr, above the FY25 peak (₹68 Cr). The stock trades ~75% above its 3-yr P/E average but ~28% below its 3-yr P/B average.
Peer multiples
| Company | P/E | P/B | RoE | PAT growth FY26 |
|---|---|---|---|---|
| 5paisa | 36.8x | 1.44x | 7.1% | -35% |
| Groww | 49.5x | 12.5x | ~25% | +14% |
| Angel One | 26.4x | 4.4x | ~15% | -22% |
| Motilal Oswal | ~31.7x (27.5x op.) | n.d. | n.d. | +16% op. |
Street coverage — none active
| House | Rating | Target ₹ | Date | Price at reco | Status |
|---|---|---|---|---|---|
| ICICI Direct | BUY | 360 | 17 Mar 2021 | 276.25 | Stale; achieved |
| ICICI Direct | BUY | 600 | 16 Jul 2021 | 552.20 | Stale |
| ICICI Direct | BUY | 450 | 1 May 2022 | 360.50 | Stale |
| ICICI Direct | BUY (Q1 FY23) | 375 | 20 Jul 2022 | 348.70 | Stale |
| ICICI Direct | Downgrade to HOLD | 375 | Dec 2022 | — | Last institutional view |
| Quant / aggregator (not coverage) | Rating | Fair value / target ₹ | Date |
|---|---|---|---|
| TipRanks (six AI-model "analysts") | All Hold | 368–389 | ~6 Oct 2026; "no analyst ratings in last 3 months" |
| MarketsMojo | Strong Sell → Sell (48/100, 17 Jul) → Hold (24 Sep / 5 Oct) | 280–300 | Quality "Below Average"; valuation "Fair"; technicals bullish |
| Stockopedia | — | 375 | Undated; = stale ICICI TP |
| Univest blog | — | 390 | May 2026 |
| Simply Wall St | Insufficient data | — | 2026 |
Price anchors
| Event | ₹/share |
|---|---|
| 2021 preferential (FIH, WF Asian, others) | 500 |
| 52-week high (after 17 Jul 2026) | 416.65 |
| Q1 FY27 pre-results close | 385 |
| Implied 5paisa value in Giskard swap (₹11,794 ÷ 31) | ~380 |
| Current | 347 |
| Rights issue price (promoters ~133% of entitlement) | 300 |
| Kela entry / Ward Ferry exit (Nov 2025) | ~290–293 / 289.16 |
| 52-week low | 245 |
| Jun-26 book value per share | 240.9 |
Scenarios (12–18 months) Analyst View
| Case | Assumptions | FY28 PAT ₹ Cr | Multiple | Value ₹/sh |
|---|---|---|---|---|
| Bear | Actives keep falling; rating action; tax crystallises; Fairfax block | 35–40 | 1.1x book | ~265 |
| Base | MTF grows, brokerage flat; Giskard closes; RoNW ~6–7% | 55–65 | 1.4x book (~25x P/E) | ~340 |
| Bull | Share stabilises; cost-to-income <70%; Trendlyne lifts ARPU; RoNW ~10% | 90–100 | 2.0x book (3-yr avg) | ~500 |
24-month news flow
| Date | Event |
|---|---|
| Jul-2024 | MCX ₹2.60 Cr penalty + 14-day bar; SEBI ₹2 lakh (UCC) |
| 1 Nov 2024 | MTF rate cut "to stay competitive" |
| Oct–Dec 2024 | SEBI F&O framework; Q4 FY25 broking -23% QoQ |
| 14/17 Jan 2025 | Gaurav Seth CEO, then MD & CEO |
| 28 Jan–3 Feb 2025 | IT search of IIFL group incl. 5paisa |
| 12 Feb / 26 Aug 2025 | CRISIL reaffirmations; CP ₹100 → ₹200 Cr |
| 9–10 Oct 2025 | Q2 FY26 PAT -57%; stock +15%; Gorelov joins |
| 13 Oct 2025 | SEBI OBPP order ₹3 lakh (PFUTP) |
| 17–19 Nov 2025 | Ward Ferry exit; Kela's Shubhi buys 7.46%; stock +21% in two days |
| 14 Jan 2026 | Q3 call with zero questions |
| 20 Jan 2026 | CRISIL bulletin: IDFC First ₹150 Cr, ABCL ₹40 Cr, IDBI BG ₹75 Cr |
| 24 Feb – 13 Apr 2026 | Rights approved, priced (1:2 at ₹300), subscribed 1.24x, allotted |
| 30 Mar / 1 Apr 2026 | IT order ₹0.75 Cr |
| 30 Apr 2026 | FY26 results; AR "reset rather than a setback" |
| 5 May 2026 | IT block assessment ₹33.02 Cr |
| 22 May 2026 | Committees reconstituted |
| 16–18 Jun 2026 | CCO resigns; board meeting postponed |
| 1 Jul 2026 | RBI intraday ban; ₹227 Cr to margin |
| 16–17 Jul 2026 | New CS; Q1 FY27; stock -4.4% over two sessions |
| 28–29 Jul 2026 | Giskard approved; promoter-purchase line withdrawn |
| 21–28 Aug 2026 | Corrigendum; CRISIL reaffirm, CP ₹400 Cr; postal ballot 99.99% |
| 1–2 Sep 2026 | 19th AGM: 16 resolutions incl. 12 IIFL RPTs, NCDs, NED commission |
| 18 / 30 Sep 2026 | Investing-product head and CTO resign; stock ~₹314 on 18 Sep |
| 30 Sep / 1 Oct 2026 | GST SCN ₹15.31 Cr |
| 9 Oct 2026 | Preferential update (promoters 34.53% fully diluted); CPs redeemed |
| 13 Oct 2026 | Q2 FY27 call intimation; stock ~₹347 |
Final Verdict
Bull case
- Capital floor: NW ~₹1,130 Cr, P/B 1.44x, promoters in at ₹300 with ~₹206 Cr, Kela at ~₹290 — downside cushioned near book.
- MTF engine: funding book ₹260 → ₹422 Cr in ~15 months at ~18% client pricing; deploying idle rights capital could lift RoNW toward double digits.
- AI re-rating: Trendlyne (~1.5 Mn MAU) + MCP/AlgoSpace/APIs could reposition it as an AI-led investing platform; founders took stock at ~₹380.
Bear case
- Structural decline: actives -81% since FY22, share below CRISIL's trigger, revenue flat for three years against Groww's scale.
- Governance and control: CTO/CCO/product-head exits, NSE "systemic weaknesses", PFUTP finding, disclosure errors, Giskard at ~13x sales with retracted promoter line.
- Overhangs: ₹49–71 Cr tax, Fairfax's 32.76% possible exit, a 36.8x P/E that needs PAT above the FY25 peak.
Base case (12–18 months)
MTF interest grows, brokerage stays flat, opex absorbs growth. PAT ₹45–60 Cr, RoNW ~6–7%. Giskard closes ~Jan 2027 (+4.4% shares). CRISIL holds A+ on parentage. Stock range-bound ₹290–400, gravitating to ~1.4x book (~₹340).
Five things to remember
- Use 36.8x P/E and 1.44x P/B. The ~26x and 2.5x on aggregators use pre-rights data.
- Only ~3.3 lakh of 52.6 lakh customers trade. Share is 0.63% (CRISIL), not "~2%".
- 43% of revenue is interest, and FD float interest is labelled "cross-sell". Real cross-sell is ₹1.06 Cr.
- The ₹33.02 Cr tax demand is not in the AR and is unprovided. Contingent liabilities are ₹625.8 Cr, mostly exchange BGs.
- Fairfax (32.76%) roughly equals the promoters (36.5%). There are no DIIs and no sell-side coverage.
Five questions to ask before investing
- Does Q2 FY27 show the promised "acceleration": active clients, new adds, cost-to-income below 80% excluding capitalisation?
- Who receives the ₹121.57 Cr Giskard cash, does any seller link to the IIFL group, and what are Trendlyne's profits?
- Is the AY23-24 ₹21.85 Cr demand subsumed in the ₹33.02 Cr block order, and will any amount be provided?
- Who replaces the CTO, and what remediation answers NSE's QSB "systemic weaknesses" warning?
- What are Fairfax's intentions for its 32.76%, and will any FY27 RPT headroom (ICDs given) be used?
Monitorables
| Metric | Latest | Positive signal | Negative signal |
|---|---|---|---|
| NSE active clients | 3.31 lakh | >3.5 lakh | <3.0 lakh |
| Cost-to-income (CRISIL) | 81% | <70% | >85% |
| Quarterly PAT | ₹11.6 Cr | >₹15 Cr ex-capitalisation | <₹10 Cr |
| Avg funding book | ₹422 Cr | >₹600 Cr | Stalls |
| Market share | 0.63% | ≥0.75% | Rating action |
| Fairfax holding | 32.76% | Stable | Block sale |
Sources
All accessed 13 Oct 2026. Merged and de-duplicated from the financials, business, governance, narrative, market, street-sentiment and AR gap-fill inputs. Limitations: the BSE PDFs returned 403, NSE archives timed out, and Reddit, X and Google Play could not be fetched. This synthesis did not re-search or grep the AR; figures were taken from the input modules.